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Atopic eczema is an incurable disorder of the skin. Sufferers are afflicted with 
hypersensitivity to environmental agents such as soaps (detergents), animal dander, pollen, 
specific foods and sometimes even water. Genetic mutations in atopic eczema compromise 
the development of the stratum corneum resulting in xerotic skin that is prone to cracking 
and increased permeability which leads to irritation due to the influx of exogenous material 
through the skin. The causes of atopic eczema are due to a combination of genetic and 
environmental factors and it is, therefore, a difficult disease to manage. Emollients and 
topical corticosteroids are the mainstay treatments for eczema. However, they do not treat 
the underlying cause of the flare-ups frequently seen in the condition; the damaged skin 
barrier. Defects in the skin barrier arise from premature desquamation of the stratum 
corneum. The main contributors to barrier breakdown are the up-regulation of skin 
proteases that are located in the skin. Since zinc is a known protease inhibitor, it would 
thus follow that a topical treatment for skin barrier repair should be developed. Therefore, 
the main objectives of this thesis are to successfully incorporate zinc into a formulation to 
develop a novel class of treatment for eczema and to assess the delivery of the element into 
the skin. 
In this thesis, methods to assess and characterise changes to skin barrier function and to 
extract and quantify zinc in the stratum corneum have been established. The development 
of two novel topically applied formulations containing zinc lactate as the active ingredient 
(1% w/w zinc lactate cream and a 2% w/v zinc lactate formulation) has been achieved and 
the uptake of zinc from the preparations in vitro determined. Further, the in vitro 
percutaneous penetration of zinc from three commercially available preparations has been 
investigated and compared to that recovered from the stratum corneum after passive 
diffusion with the novel zinc formulations. Additionally, in vivo uptake of zinc into human 
®
stratum corneum from Sudocrem is reported. Scanning electron microscopy has revealed 
the distribution of zinc on the surface of skin treated with various formulations and has 
also allowed the efficiency of two cleaning procedures to be ascertained. 
The delivery of zinc from the novel topical formulation; 1% w/w zinc lactate cream, was 
more efficient than that the three commercial formulations and shows promise as a new 













Atopic eczema (AE) is the most common skin disorder in the United Kingdom and 
accounts for approximately 30% of dermatological consultations. It is estimated that 9% of 
the UK population is affected by AE at any one time and at least 40% of people will have 
at least one episode during their lifetime.(1, 2) The average age of onset of AE is 3-7 
months, with approximately 25% of infants under the age of five, and 2-10% of adults 
affected.(1-5) The prevalence of AE has a higher frequency in urban rather than rural areas 
and also in smaller families with higher socioeconomic backgrounds which suggests that 
the development of AE may be due to the lack of exposure to infectious agents or antigenic 
triggers and increased contact with antigenic pollutants.(6, 7) 
AE is a highly distressing, chronic, recurring inflammatory disorder of the skin. Affected 
individuals are hyperreactive to environmental triggers that are normally innocuous to 
healthy individuals with no history of hypersensitivity.(8) In infants, the effects are initially 
presented on the face and eventually advance to the rest of the body (Fig. 1) .(2, 3) Areas 
of skin affected typically include the neck, scalp, trunk and flexures of the arms and behind 
the knees.(2-4) Sufferers present with xerotic, erythematous, oozing lesions which are 
intensely pruritic and simultaneously excruciating. The pruritic characteristics of eczema 
induce scratching which can result in the formation of lesions and, in some cases, bleeding. 
Lichenification and excoriation are also commonly observed features of eczema.(9) 




AE significantly affects the quality of life for affected individuals and their families. 
Children (and adults) suffer from sleep-disturbance and, in some cases, the disease may 
have a severe impact on their physical, social and psychological development since the 
areas affected, the face, neck and flexural positions of the arms and legs, are visible and 
often associated with disfigurement.(11, 12) A study involving paediatric nurses showed 
that even medical professionals showed signs of avoidance to children affected with 
eczema. The psychological impact of this on children may be long-lasting and carry on 
into adolescence or adulthood.(12) Research has also revealed that preschool children 
affected with eczema tend to have higher rates of behavioural problems and showed more 
fearfulness, emotional attachment and dependency on their parents.(13) In the case of 
children of school-age, those affected with moderate to severe eczema exhibited twice the 
rate of psychological disturbance than their non-atopic peers.(14) These disturbances can 
be partly attributed to bullying, unwanted comments and frequent feelings of 
embarrassment in social settings which may eventually lead to social isolation and 
depression.(15) Not only is the child affected by AE, but the parents also suffer physical 
and mental exhaustion by caring for the restless child throughout the night and are plagued 
by feelings of hopelessness, guilt, frustration and depression.(15, 16) Though AE is not 
perceived as a serious medical condition, it can have a significant impact on quality of life. 
Limitations on the child’s daily activities, for example, going on holidays, choice of 
clothing, owning of pets, all contribute to decrease the quality of life experienced by AE 
sufferers.(15) A study comparing the quality of life in children affected with 
dermatological disorders and others with chronic childhood diseases found that AE and 
psoriasis had the greatest impact on children with skin disorders. Of all chronic childhood 
diseases, only cerebral palsy scored higher than AE.(17) 
AE is affiliated with a number of other allergies such as allergic rhinitis, asthma, food 
allergies and hayfever. This is known as the ‘Atopic March’ (AM).(6) There is controversy 
surrounding whether the AM really does exist and if it can be prevented.(18) However, 
there is compelling evidence that suggests otherwise. Some researchers believe that the 
AM is ‘…the natural history of atopic manifestations, characterised by a typical sequence 
of progression of clinical signs of atopic disease…’ and consider AE as the basis of the 
AM which subsequently leads to the development of asthma and other allergic diseases.(6) 
It has been reported that 30-60% of paediatric patients will progress on to develop other 




‘take turns’ where one becomes more dominant whilst the others subside.(6) Longitudinal 
studies discovered that as AE improved, 43% and 45% of sufferers proceeded to develop 
asthma or allergic rhinitis, respectively, within 8 years and that the patients, who did not 
develop either of these allergies, were only affected with mild AE.(20) This suggests that 
the risk factor for the development of other allergies, especially asthma, depends on the 
severity of AE.(6) The study found that 70% of patients affected by severe AE went on to 
suffer from asthma compared to 30% of those only mildly affected (compared to the 
general (non-atopic) population of only 8%). A 7-year study involving 1314 children 
revealed that 69% had developed AE by the age of three months and were sensitised 
against aeroallergens by the age of five. Those who had higher chances of developing the 
disease, (i.e., already had 2 family members suffering from atopy) had a 77% risk of 
sensitisation.(21, 22) Furthermore, a study conducted by Novembre et al. involving 77 
children affected with intrinsic AE (AEi) (diagnosed according to Hanifin and Rajka) 
concluded that, at 2 years of age, 22% had asthma and 64% tested positive for at least one 
allergy via skin prick tests (SPT) to food and inhalant allergens. However, at age 11, only 
46% still had AE but surprisingly 43% now had asthma and those testing positive to STP 
had risen to 84%. Interestingly, none of the ‘nonatopic’ children (15% of the total number), 
that is, those who tested negative for SPT at ages 2 and 11, had developed asthma by the 
time of the second evaluation.(23) Such evidence of AE being linked to respiratory and 
food-allergies all share a common pathogenesis and genetic basis and it has been proven in 
seven linkage studies that these diseases all have 9 different chromosomal regions 
associated to asthma.(24) 
AE is classified into two main categories; the intrinsic non-allergic form (AEi), and the 
extrinsic IgE-mediated allergic form (AEe).(25, 26) The aetiology of both forms is thought 
to be a multifactorial combination of genetic mutations and a hypersensitivity to 
environmental stimuli.(8) Scientific evidence suggests that the genetic mutations are 
responsible for (i) producing a defective skin barrier, and (ii) hyperreactivity to certain 
external stimuli that are innocuous to healthy non-atopic individuals.(8) According to 
literature sources, AEe is the most prevalent form of the two with approximately 70-85% of 
AE patients affected. It is associated with high levels of total and allergen-specific IgE in 
the blood or skin and patients are frequently also affected by other allergic conditions such 
as allergic bronchial asthma or allergic rhinoconjuctivitis.(27-29) Park et al found that all 




aeroallergens. Infants who were affected by both forms of allergies had higher total IgE 
levels than those with only food allergies. This suggests that allergy exposure is 
proportional to IgE levels.(27) Furthermore, it was discovered that patients with both 
allergies scored higher on the SCORAD index (severity scoring of atopic dermatitis) as a 
result of allergen exposure and thus had more severe clinical presentations of the disease 
(compared to patients affected with AEi).(27) With AEi, patients test negative to SPT for 
common food and inhalant allergens, have normal levels of total serum IgE, no detectable 
specific IgE to food and aeroallergens, and do not suffer from other atopic diseases such as 
those mentioned previously.(27, 29, 30) Nonetheless, AEi patients still possess the typical 
phenotype of AD and manifest identical skin lesions to AEe patients.(27, 28) Between 10­
45% of AE patients suffer from this type of the disease.(27) According to Park et al, 
infants diagnosed with AEi had lower eosinophil counts and eosinophil cationic protein 
levels (as with adult patients). They found the opposite to be true with AEe. Their results 
indicate that these parameters are well correlated with the clinical severity experienced by 
patients and that pathogenesis of AE is affected by the role that eosinophils play in the 
inflammation of the disease state.(27) 
It is evident that the pathology of AE is very complex and is due to a combination of 
genetic and environmental triggers. Research has shown that AE is not attributed to a 
single gene but many genes which have been identified and linked to other allergic 
disorders.(19) The most prominent gene associated with AE is the profilaggrin gene, FLG, 
that codes for filaggrin.(31) Loss-of-function mutations in FLG have been shown to be a 
major genetic predisposing factor for AE. These mutations reduce the amounts of 
profilaggrin produced by the keratohyalin granules in the epidermis.(32) This results in 
decreased levels of filaggrin (profilaggrin is dephosphorylated and proteolysed to form 
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filaggrin) which, in turn, causes a decrease in the levels of natural moisturising factor 
(NMF) in the stratum corneum (SC) (NMF is the final product of filaggrin) (Fig. 2).(33) 
Deficiencies in filaggrin lead to a defective skin barrier since the lack of water-absorbing 
NMF results in shrinkage of corneocytes causing fissures to appear between them, 
resulting in increased transepidermal water loss and the influx of pathogens, allergens and 




Fig. 2 (A) Normal healthy skin where proteases are in balance with protease inhibitors. Normal production of 
NMF keeps the SC hydrated resulting in tight-junctions between corneocytes. (B) Genetic predisposition to 
atopic eczema increases desquamation and decreases the production of NMF. As a result, the stratum 
corneum is thinner, xerotic and prone to the formation of fissures. (C) Environmental proteases such as soaps 
and detergents further increase the rate of desquamation and contribute the breakdown of the skin barrier.(35) 
Environmental contributions to the manifestation of eczematous lesions via the already 
damaged skin barrier include increase in the frequency of washing, use of detergents, 
house-dust mites, pollen, fungal allergens, and the list goes on (Fig. 3). Furthermore, 
climate change and stress (life-events such as parental divorce or death in the family) also 







Fig. 3 The defective skin barrier in atopic eczema facilitates the influx of irritants and allergens. Endogenous 
proteases residing within the epidermis and external proteases contribute the breakdown of the skin barrier. 
Hyperactive immune responses result in inflammation at the affected sites and together with the proteases 
lead to the formation of eczematous lesions.(35) 
However, the use of detergents probably has the greatest effect on AE suffers when the 
damaged skin barrier is subjected to washing with hard water and detergents which strip 
away the lipids in the skin that keep the SC hydrated and flexible (Fig. 4).(38) 
Furthermore, surfactants contained in the detergents further irritate the skin causing 
inflammation which results in itching and scratching which then produces lesions. These 
lesions, due to the protracted healing process, are exposed to these causal factors 




Fig. 4 Detergents and other environmental factor s combined with a genetic predisposition to the 
development of eczema causes the breakdown of the skin barrier resulting in flare-ups of the disease.(8) 
Though an individual may have the defective genes that predispose them to AE, physical 
signs of the disease may not be observed. This is due to the gene-environment dosage 
interaction where, for example, if an individual has mutations in 5 genes that makes them 
more inclined to exhibit the disease, it may take fewer environmental factors to trigger it 
and vice versa - if the individual only has 2 mutations in those genes, then multiple 
exposures to environmental stimulants will induce the disease state.(8) Absence of 
manifestations of symptoms may simply mean that the environmental dosage threshold has 
not been breached. 
The skin is a complex structure consisting of four compartments; the hypodermis, dermis, 




Fig. 5 Structure of the skin (39) 
With respect to the body’s first line of defence against external assault by foreign 
substances, the SC is the most relevant. Any breach of this layer would leave the body 
vulnerable to attack and infection.(8, 40) It forms the barrier to penetration of substances 
into, and the exit of water out of, the body. It is also the thinnest and smallest of all skin 
compartments. 
The SC consists of corneocytes, corneodesmosomes and the lipid lamellae. With the 
corneocytes being analogous to bricks, the corneodesmosomes as iron rods, and the lipid 
lamellae as cement, the SC can be thought of as a brick wall being locked together by the 
corneodesmosomes and bonded by the lipid lamellae.(41) The corneodesmosomes provide 
the SC with tensile strength whilst the lipid lamellae help prevent water loss.(41) The 
homeostasis of the SC is a finely controlled process by which the SC thickness is regulated 
by proteases and protease inhibitors. Proteases breakdown extracellular corneodesmosomal 




surface. In particular, the stratum corneum chymotrypic enzyme (SSCE) and the stratum 
corneum tryptic enzyme (SCTE) are the two most prominent proteases.(42, 43) SCTE is 
able to activate SSCE and itself in order to bring about desquamation. The activity of 
SCCE and SCTE is regulated by protease inhibitors such as the leukoprotease 
inhibitor.(42, 43) Over-expression of SCCE leads to the premature desquamation of the SC 
resulting in decreased thickness as basal cell proliferation is not able to replace the lost 
cells quickly enough and, as a consequence, the skin is more vulnerable to the penetration 
of irritants and allergens and also to increased water loss. When the barrier is compromised 
as such, secondary proteases produced by cells within the inflammatory infiltrate are 
produced which further contribute to desquamation.(8) The level of these proteases is 
proportional to the severity of the eczematous lesion.(44) In addition, exogenous proteases 
from house-dust mites and detergents also augment desquamation which, in AE sufferers, 
is extremely detrimental to the already weakened skin barrier (Fig. 6). 
Fig. 6 The stratum corneum is analogous to a brick wall. (A) In a healthy skin barrier the iron rods 
(corneodesmosomes) breakdown as part of the normal desquamation process. (B) Predisposition to eczema 
causes the ‘rods to rust’ leading to premature breakdown of the stratum corneum. (C) Contact with external 
proteases such as detergents further increases the rate of rusting and desquamation. (D) This facilitates the 
influx of irritants and allergens through the skin to cause inflammation and infection. (8) 
It is well established that the skin of AE patients tends to have higher TEWL and lower 
electrical resistance than normal controls suggesting (i) an impaired skin barrier, and (ii) 




Treatments for AE depend on the severity of the disease and involve a combination of 
prophylactic approaches and therapeutic regimens tailored specifically for each individual. 
Generally, patients are advised to avoid contact with allergens and irritants, use soap 
substitutes, and regular use of emollients to alleviate dryness and increase the flexibility of 
the skin. The avoidance of certain foods which may trigger flare-ups may also be 
recommended.(46) However, the treatment of AE revolves around the use of topical 
corticosteroids (TCS) including hydrocortisone, betamethasone and fluticasone 
proprionate.(1, 5, 47) They are normally used when emollient therapy is ineffective and 
may be used in conjunction with topical antibiotics such as mupirocin ointment.(46) TCS 
therapy may, however, only be used to control the manifestations and their use should be 
limited up to the point when improvement of the condition is seen, when the use of the 
drug should be gradually decreased or withdrawn.(48) The rationale is that the adverse 
effects caused by the long-term/overuse of these preparations cause local and systemic 
side-effects. The most prominent side-effect is skin thinning caused by impaired fibroblast 
proliferation induced by TCS. Skin atrophy decreases barrier function and increases the 
likelihood of further damage to the skin which may exacerbate the existing disorder.(49) 
Fig. 7 Striae caused by topical corticosteroid use (50) 
Local adverse effects include (i) atrophic changes - telangiectasia, striae (Fig. 7), ulceration 
and purpura, (ii) infections - granuloma gluteale infantum, masked microbial infections 
such as tinea incognito, (iii) steroid rebound or addiction, (iv) acne, and so on. Moreover, 
the systemic effects include hypothalamic-pituitary-adrenal (HPA) axis suppression, 
cataract, glaucoma, Cushing’s syndrome, femoral head osteonecrosis and even, in rare 




long-term use of potent and superpotent topical formulations have caused growth 
retardation in children.(51) For severe AE, immunosuppressive therapy involving topical 
calcineurin inhibitors - cylcosporin, tacrolimus and pimecrolimus - is used for controlling 
the disease. Although these drugs are very effective, concerns about their long-term use 
remain.(47, 48) Topical antihistamines are also prescribed for the treatment of AE. 
However, they can cause drowsiness.(1, 5, 47) Other treatments such as oral antibiotics 
(used to treat staphylococcal colonisation or infection of the skin) are also worth 
mentioning.(52) The vast majority of treatments for AE described above address the 
condition of the disease only after the manifestations have occurred and emollient therapy 
is only used to manage the problem of dry skin. The use of emollients is done on a trial and 
error basis and not all creams, ointments and lotions are suitable for each individual. 
Furthermore, this seemingly simple treatment is not free from problems. For example, the 
use of Aqueous Cream BP has been reported to cause burning, stinging and redness of the 
skin after application. In fact, the frequency of adverse reactions caused by Aqueous 
Cream BP is the highest amongst all emollients, yet it is the most widely prescribed 
formulation for the treatment of xerosis.(53) Aqueous Cream BP is used as an emollient to 
relieve skin dryness, improve flexibility and also serves as a mechanical barrier to irritants 
and allergens. Cutaneous reactions caused by Aqueous Cream BP could be due to two 
ingredients; the preservative phenoxyethanol and/or the surfactant sodium lauryl sulphate 
(SLS). SLS is widely used as a model skin irritant and is known to act as a penetration 
enhancer.(54) The use of SLS in formulations intended to treat AE defeats the object since 
it exacerbates the disease by enhancing the penetration of irritants and allergens that causes 
atopic manifestations. Recent research has shown that short term application of Aqueous 
cream BP on the forearm of healthy non-atopic volunteers induced skin atropy (12%) and 
increased transepidermal water loss (20%) most likely the result of SLS contained in the 
preparation.(55) The use of this emollient clearly leads to negative effects on the stratum 
corneum and therefore, it is plausible to assume that this effect would be enhanced in AE 
suffers and cause further damage to their delicate skin barrier, in which case the use of 
Aqueous Cream BP may benefit from a review. 
In addition, as mentioned previously, the process of desquamation is finely maintained by 
a balance of skin proteases and their inhibitors. However, in AE, the up-regulation of these 
proteases, (chiefly SCCE and SCTE, and stratum corneum thiol protease (SCTP)) lead to 




zinc is a known protease inhibitor, and can therefore counteract the effects of the proteases, 
it would be feasible to propose a zinc-containing formulation for topical application for 
treatment of AE to aid skin barrier repair.(42, 43) 
Previous research carried out have shown that the activity of the two main proteases 
responsible for increased desquamation; kallikrein 5 and 7, which is known as stratum 
corneum tryptic enzyme (SCTE) and stratum corneum chymotryptic enzyme (SCCE), 
respectively, can be inhibited by zinc. The mechanism of action relies on the ability of zinc 
to bind to the active sites of the proteases to effectually ‘deactivate’ them. Once 
deactivated, premature desquamation will be decreased and the proteases can no longer 
breakdown corneodesmosomes in the stratum corneum in an uncontrolled manner.(42, 43) 
This reduction in the rate of desquamation will allow time for the proliferation and 
maturation of keratinocytes through the epidermis to eventually form the stratum corneum 
and the intercellular lipid lamellae which protects the body from influx of harmful 
substances. Increased rates of desquamation prevent the intercellular lipid lamellae from 
forming properly due to lack of time for the cell contents to be extruded into the 
intercellular space to be processed into the continuous lipid domain that keeps the skin 
intact.(33) Zinc is known to stabilise cell membranes and also reported to play a central 
role in cell mitosis, migration and maturation in dermal tissue.(56) Studies have also 
shown that zinc concentrations increase by approximately 15-20% in the areas around 
wounds within 24 hours. Further, it has been reported that topical application of zinc is 
more effective than oral zinc therapy at epithelialisation of wounds in normozincemic 
individuals and reducing infections.(56) 
The primary objective of the project is to, therefore, formulate and safely deliver a 
topically applied drug to improve skin barrier function in AE and other related diseases. 
The aims of the project, therefore, are to (i) develop an in vivo methodology to characterise 
and assess skin barrier function, (ii) develop a method to extract and quantify the 
percutaneous uptake of zinc into the stratum corneum in vitro, (iii) determine the in vitro 
percutaneous penetration of zinc into the skin from commercial preparations, (iv) prepare 
and determine the in vitro percutaneous penetration of zinc into the skin from novel zinc 
formulations, (v) examine and image skin treated with various zinc preparations using 
scanning electron microscopy, and (vi) investigate the in vivo absorption of zinc from 
®




Should zinc be delivered efficiently and effectively to the skin, further development of the 
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Summary 
Background - The development of a novel topical formulation for the treatment of atopic 
eczema is currently in progress. Like all products, subsequent to formulation, efficacy 
testing needs to be carried out. In order to do so, it will be necessary to establish a means to 
detect the formulation effects on the skin and, in this case, to be able to detect differences 
between healthy and diseased or damaged skin. 
Objectives - To develop a tool that can suitably measure the physical properties of the skin 
to distinguish between healthy, intact skin and damaged or disease skin to provide an 
indication to the effects of a novel topical formulation. 
Methods - Six human volunteers were recruited to apply Aqueous Cream BP to one side of 
their mid-volar forearms in an attempt to elicit a change in the skin barrier. The other side 
of the forearm was left untreated to act as a control. Tape stripping and transepidermal 
water loss measurements (TEWL) were used to characterise and assess the skin barrier 
function after treatment four weeks treatment. 
Results - The data showed that the application of Aqueous Cream BP for four weeks was 
successful in causing a sufficient change in the skin barrier that was detectable by using the 
method developed to measure changes in the physical properties of the skin. 
Conclusions - The tool developed using tape stripping and TEWL measurements in tandem 
for the characterisation and assessment of skin barrier function was suitably fit for purpose, 
reproducible, reliable and robust. The study also revealed that the short-term application of 
Aqueous Cream BP caused the barrier properties of the skin to diminish. 
Keywords: Tape stripping, transepidermal water loss (TEWL), skin barrier, aqueous cream 
BP, sodium lauryl sulphate (SLS) 
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Introduction 
The intention of this study is to develop a suitable tool with which to assess and 
characterise the skin barrier. Its necessity originates from the current development of a 
novel formulation for the treatment of skin disorders such as eczema where patients are 
afflicted with an abnormal skin barrier. This defect in the protective layer, the stratum 
corneum, allows higher levels of transdermal water loss to occur from the surface of the 
skin.(1) More alarmingly, this also permits the influx of irritants, chemicals and 
xenobiotics through the barrier which eventually leads to flare-ups of eczematous lesions. 
The formulation is anticipated to aid repair of the skin barrier in the hope of reducing the 
frequency of flare-ups experienced. Therefore, to be able to determine the effectiveness of 
the formulation, a tool needs to be developed that is able to detect differences in the skin 
barrier before and after treatment, i.e. a damaged and healthy, healed skin barrier. 
The concept of this tool is based on Fick’s 1st Law of Diffusion which states that the 
passive transport of water molecules across membranes progress from regions of high 
concentration to regions of low concentration, i.e. mass transfer.(2) 
K · ΔC · D 
J  = (Eq.1) 
H 
This movement of water across membranes can be explained via the above equation where 
flux, J, (which, in this case is water) it is equal to the product of the SC-viable epidermis 
partition coefficient of water, K (0.06), multiplied by the concentration gradient of water 
-3
across the stratum corneum, ΔC (~ 1g/cm ), multiplied by the diffusivity of water within 
the stratum corneum, D, divided by the diffusional pathlength, H.(2,3) In simple terms, 
flux is inversely proportional to stratum corneum thickness and by using tape stripping, we 
can determine the thickness of the barrier (Eq. 1). This information can be used to indicate 
the condition of the skin barrier since a diminished stratum corneum, in theory, should 




A modified version of Fick’s 1st Law of Diffusion allows the flux at various depths of the 
stratum corneum layers to be measured during tape stripping and equation 2 has, 
incorporated into it, Jx, the value of TEWL at a depth of x within the stratum corneum and, 
x, the thickness of stratum corneum removed.(1) 
K · D · ΔC 
Jx = (Eq.2) 
(H - x) 
Since we know that the stratum corneum forms the rate-limiting barrier to insensible water 
loss and from the equations we also know that TEWL is inversely proportional to stratum 
corneum thickness we can use these parameters to form the core of the tool that will be 
used to assess and characterise skin barrier function and differentiate between healthy and 
damaged skin barrier. 
Materials and Methods 
Materials 
Aqueous Cream BP (cetostearyl alcohol, sodium lauryl sulphate, liquid paraffin, white soft 
paraffin, phenoxyethanol 1% w/w and purified water) was purchased from Pinewood 
Healthcare (Clonmel, Ireland). Scotch No. 845 book tape was from 3M (St. Paul, MN, 
TM
USA), Micropore tape from 3M (Nadarzyn, Poland), and the tape stripping template (2 
cm diameter aperture) was constructed from the previously mentioned book tape. 
Study Population 
Six healthy female subjects aged between 20-36 years with no history of skin disease, and 
who did not suffer from any dermatological conditions at the time of the study participated 
in the investigation. Each person was provided with an information document containing 
the project details. Written informed consent was obtained from each participant and any 
questions raised were answered appropriately and duly. The study was approved by the 
local research ethics committee (Royal United Hospital, Bath, UK). 
Throughout the duration of the study, participants were required to refrain from applying 
any topical formulations to the test areas, i.e. forearms, and to avoid taking part in any 
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activities that may affect the properties of the skin such as sunbathing, swimming, 
exfoliation and beauty treatments. In addition, participants were also instructed to allow a 
grace period of 2-3 hours before engaging in activities such as taking a bath/shower or 
sporting events after the application of Aqueous Cream BP. 
Experimental Procedure - Treatment with Aqueous Cream BP 
The experiments were conducted on the mid-volar forearm region with both control and 
test areas in close propinquity to each other (without overlapping) to minimise intra-
individual and regional differences in the skin barrier. To partition the test and control 
regions of the skin a hypothetical line was envisaged from wrist to elbow with each region 
containing two test sites. 2 ml of Aqueous Cream BP was delivered to the test area using a 
syringe (without the needle) and massaged uniformly. The formulation remained on the 
area for ten minutes after which the excess was removed using soft facial tissue, taking 
care not to contaminate the contralateral (control) region. The application was carried out 
bi-daily (morning and night) for a period of four weeks. Volunteers were asked to conduct 
the last application 24 hours prior to tape-stripping. The procedure was also conducted on 
the opposite arm where the test and control regions were reversed (Fig. 1) 
Fig. 1 Illustration of the treated and control regions of the mid-volar forearm where the treatment sites are 
reversed for opposite arms. The lines delineate the boundary between treated and untreated sites. 
Tape Stripping 
Volunteers were required to acclimatise to the laboratory environment for at least 20 
minutes before commencing the experiment. To delineate the tape-stripping area, a 
polyester template with a circular aperture of 2 cm diameter was attached to the mid-volar 
forearm. Baseline TEWL was measured using a closed-chamber evaporimeter (Biox 
Aquaflux AF102, Biox Systems Ltd. London, UK). Multidirectional tape stripping with 
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pre-weighed tape strips (Sartorius AG SE-2F semi-microbalance, Sartorius AG, Göttingen, 
Germany, 0.1 μg precision) and TEWL measurements were carried out until approximately 
75% SC removal was achieved. The tape strips, with skin adhered, were then re-weighed 
to allow stratum corneum mass and hence, thickness to be calculated. To ensure uniform 
adhesion between the tape and skin, systematic application of homogeneous pressure using 
a weighted roller was employed. 
Data and Statistical Analysis 
SC thickness removed was calculated using the following equation where SC density is 
-3
assumed to be 1 g cm : (4) 
mass of SC removed 
SC thickness removed  = (Eq.2) 
area of SC removed  x SC density 
Preliminary data analysis was carried out using Fick’s 1st Law of Diffusion as explained 
previously (Eq. 3):(2) 
K · D · ΔC 
Jx = (Eq.3) 
(H - x) 
A linear relationship derived from the above equation allows for the total thickness of the 
stratum corneum to be determined (Eq 4):(2) 
1 H 1 
=  x (Eq.4)
TEWLx K · D · ΔC K · D · ΔC 
such that plotting 1/TEWLx as a function of cumulative thickness removed (x) yields a 
straight line, the x-intercept of which equals the total SC thickness, H (Fig 2). 
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Fig. 2 Example graph of 1/TEWLx versus SC thickness removed for one volunteer. A linear fit of Fick’s 1
st 
Law of Diffusion allows the total SC thickness to be deduced from the x-intercept. 
However, quite often, it is apparent that the initial values of TEWL do not change 
significantly as the first tape strips are removed (Fig. 2). This may be due to the stratum 
disjunctum which is not contributing to the overall barrier function. The result is that the 
effective value of H may be over-estimated. To circumvent this problem, the results have 
been analysed with a modified model, recently published by Russell and Delgado-Charro 
(2008).(5) 
K · D · ΔC 
Y  = B  + (Eq.5) 
(H - x) 
where B is the baseline TEWL and K · D · ΔC is a constant (30). TEWL values as a 
fraction of x were fitted this equation which takes all points into consideration and 
enhances the accuracy of the SC thickness determination (Fig. 3). 
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Fig. 3 Re-plotted data from Fig 2 fitted to the modified model of Russell and Delgado-Charro (2008). For the 
-2 -1
fitting procedure, initial values of B, P and H were 14.4 gm h , 30 units, and 8.4 μm. 
®
GraphPad Prism V.4.00 (GraphPad Prism 4 Software, San Diego, CA, USA) was used to 
calculate stratum corneum thickness via non-linear regression and also all statistical 
calculations. Stratum corneum thickness and TEWL values were expressed in terms of 
standard deviations (SD) and means. Confirmation of Gaussian distribution was 
established by performing a normality test on the data and statistical significance was 
determined via a two-tailed paired t-test. The confidence interval was adjusted to 95% and 
the significance level was set at P < 0.05.  
Results 
Tape Stripping Profile 
A typical tape stripping profile of treated and untreated skin is displayed in Fig. 4. After 
four weeks treatment with SLS containing Aqueous Cream BP a change in the skin barrier 
can be detected using TEWL and tape stripping. The graph shows an increase in the 
baseline TEWL and a faster rate of increase in TEWL during tape stripping. In addition, a 
decrease in stratum corneum thickness can be observed in the treated skin. 
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Fig. 4 Representation of the changes in the tape stripping profile of treated and untreated skin 
Total Stratum Corneum Thickness and TEWL 
On closer inspection of the data, we can see an inversely proportional relationship between 
total stratum corneum thickness and TEWL, as predicted by Fick’s 1st Law of diffusion, 
between the pairs of data (Table 1).(1) Total stratum corneum thicknesses of control and 
treated skin sites ranged from 6.0 - 15.3 μm (mean 9.3 ± 2.5μm) and 4.5 - 14.1 μm (mean 













(mean 14.8 ± 2.4 g.m 
­
2 -1
h ), respectively. An overall decrease of 1.1 µm in stratum corneum thickness and an 
-2 -1 
increase of 2.5 gm h in TEWL was observed. 
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1 11.5 9.8 -1.6 -14 10.3 11.7 1.4 14
1 8.8 10.6 1.8 20 11.3 13.7 2.4 21
1 8.9 8.3 -0.6 -6 15.9 14.4 -1.5 -10
1 9.2 9.0 -0.2 -2 12.5 15.2 2.7 22
2 8.5 6.0 -2.5 -29 8.4 13.8 5.4 64
2 10.5 5.8 -4.7 -45 7.2 13.4 6.2 85
2 7.5 6.3 -1.2 -16 12.1 13.9 1.8 15
2 7.2 5.9 -1.3 -18 9.6 13.3 3.8 39
3 6.3 6.6 0.3 5 12.0 13.5 1.5 12
3 9.6 6.7 -2.8 -30 8.5 11.8 3.3 39
3 9.7 9.3 -0.4 -4 7.9 12.2 4.4 56
3 11.0 9.3 -1.6 -15 7.4 12.1 4.7 64
4 12.9 14.1 1.2 10 11.7 15.6 3.8 33
4 13.1 13.4 0.4 3 10.6 14.9 4.3 41
4 14.8 11.6 -3.2 -21 11.9 15.4 3.5 29
4 15.3 10.9 -4.3 -28 12.2 14.3 2.2 18
5 9.4 9.2 -0.2 -2 12.2 13.3 1.0 8
5 10.0 9.1 -0.9 -9 10.8 11.2 0.4 4
5 8.6 9.5 0.9 10 11.8 15.9 4.1 34
5 9.6 9.7 0.1 1 10.9 17.5 6.7 62
6 6.0 4.5 -1.4 -24 17.0 17.7 0.6 4
6 6.5 5.7 -0.9 -13 18.3 16.1 -2.2 -12
6 7.0 7.2 0.2 2 13.7 16.1 2.3 17
6 7.5 7.1 -0.3 -5 12.1 15.1 3.0 24
6 8.4 6.0 -2.4 -29 15.7 19.2 3.5 22
6 7.1 5.8 -1.3 -18 18.5 17.2 -1.3 -7
6 6.5 5.0 -1.5 -23 22.0 22.0 0.0 0
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Table 1 Differences between treated and untreated total SC thickness and TEWL are small but significant. 
An increase in SC thickness and decrease in TEWL after Aqueous Cream BP application is seen in the 
majority of cases 
Fig. 5 shows the data in a before- and after- graph. It clearly illustrates the changes in total 
stratum corneum thickness and TEWL after Aqueous Cream BP application (Fig. 5). In 20 
of 27 cases (74% of skin sites), a decrease in total stratum corneum thicknesses was 
observed post treatment with a mean decrease of 1.7 µm, a percentage change of 18 % (P < 
0.0001). Overall, where n = 27, total stratum corneum thickness decreased, by 1.1 μm, 
which translates to a percentage decrease of 12% (P = 0.0015). 
-2 -1
For baseline TEWL, a mean increase of 3.2 g.m h , correlating to a percentage increase of 
29%, was observed in 23 out of 27 cases (85% of skin sites) after Aqueous Cream BP 
-2 -1
application (P < 0.0001). Overall, an increase of 2.5 gm h , a percentage increase of 20%, 
was observed across the board (P < 0.0001). Only one pair of values showed no increase or 
decrease in TEWL after treatment with the cream. 
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Fig. 5 Graphical representation of changes in total stratum corneum thickness and TEWL 
Fick’s 1st Law of Diffusion 
Out of 27 pairs skin sites sampled, 16 of those followed Fick’s 1st Law to demonstrate that 
a decrease in stratum corneum thickness is accompanied by an increase in TEWL. Fig. 6 
permits different combinations of increases and decreases in changes of stratum corneum 
thickness and TEWL to be visualised. Increased thickness with increased TEWL, increased 
thickness with decrease TEWL, and decreased thickness with decreased TEWL, and most 
importantly, decreased thickness accompanied by increased TEWL are located in the upper 
right quadrant (green), lower right quadrant, lower left quadrant (blue) and upper left 
quadrant (red), respectively. The graph shows that the majority 16 out of 27 (56%) of the 
data points are positioned in the upper left quadrant indicating a decrease in stratum 
thickness and an increase in TEWL 
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Fig. 6 A scatter plot illustrating different combinations of changes in stratum corneum thickness and TEWL 
Discussion 
In the first part of this study, healthy human volunteers with no history of dermatological 
disease were asked to apply Aqueous Cream BP to their forearms bi-daily for four weeks 
in an attempt to perturb the skin barrier. The formulation contains approximately 1 % w/w 
of sodium lauryl sulphate (SLS). SLS is an anionic surfactant that is known to cause 
irritation to the skin and is routinely used to alter and disturb the skin barrier in 
percutaneous penetration, barrier function and barrier repair studies.(1, 6-18) SLS is also 
extensively used to form disease models such as irritant contact dermatitis in studies and 
for the investigation of skin barrier properties in atopic dermatitis sufferers.(13-15) The 
concentrations used in these studies ranged from 0.03% - 20% w/v and with the exception 
of Koopman et al, all researchers reported a change in the skin barrier which was measured 
as an increase in TEWL and/or visual score of erythema.(6-18) In accordance with 
previous research using concentrations close to, or lower than, the 1% w/v used in this 
study, the application of SLS also resulted in an increase in TEWL.(8, 11, 13, 14, 17, 18) 
The effectiveness of SLS as a barrier irritant is demonstrated by the use of a 1% w/v 
33

Development of a Tool for the Evaluation of Healthy and Damaged Skin 
solution for just 20 minutes resulting in barrier perturbation presented as increase in 
TEWL.(17) 
In our study, SLS damaged skin was compared to unperturbed healthy skin sites in order to 
test the efficiency of the TEWL and tape stripping as tools for detecting changes in skin 
barrier function. The application of Fick’s 1st Law of Diffusion involved the use of these 
two techniques that formed the second part of the experiment. These two techniques are 
well established and frequently used in the area of skin research.(1, 2, 5, 6, 8, 10, 18) 
TEWL is the non-invasive measurement of the water-vapour gradient between the skin 
surface and the external environment.(19) It is measured by placing an evaporimeter probe 
onto the surface of the skin until a stable reading is recorded and, when used exclusively, it 
can detect changes in the skin barrier even in visually intact skin.(18) 
TEWL is impeded by the intercellular lipid pathway of the stratum corneum, which forms 
the rate-limiting barrier to insensible water loss, and any damage or removal of this layer 
by tape stripping or the removal or disruption of intercellular lipids decreases the tortuous 
pathway of water to the external environment resulting in TEWL increase.(1, 9-18, 20-22) 
Hence, TEWL can be used as a diagnostic tool to assess damage to the skin barrier and 
since Fick’s 1st Law of Diffusion states that the flux (of water) is inversely proportional to 
stratum corneum thickness, tape stripping was used in conjunction to form the core of our 
tool.(1) 
Tape stripping is a procedure that uses adhesive tape to successively remove layers of the 
stratum corneum.(2, 20-22) It is often used to quantify the amount of substances absorbed 
on or into and through the skin. Drug bioavailability, bioequivalence and drug penetration 
in the stratum corneum can be determined using this simple method.(6, 18, 23-26) Barrier 
recovery studies and stratum corneum thickness information can also be obtained in this 
manner.(2, 10-12, 20-22) A more recent study looks at the application of quantum dots to 
the skin, using tape stripping and transmission electron microscopy to assess penetration. 
(27) 
In this investigation, tape stripping was used to determine stratum corneum thickness and, 
used in affiliation with TEWL, a tape stripping profile was obtained which was used to 
study the condition of the skin barrier (Fig. 4). A normal healthy skin barrier is 
-2 -1




mean stratum corneum thickness found in untreated skin of volunteers was slightly lower 
(9.3 μm) than previously reported by Schaefer and Redelmeier (19) and after treatment 
with Aqueous Cream BP, the mean value was reduced by 12% to 8.2 μm. Baseline TEWL 
-2 -1
before treatment was slightly higher at 12.3 gm h , than the range mentioned previously, 
-2 -1 
and increased to 14.8 gm h after treatment. The minute change in stratum corneum 
-2 -1 thickness by 1.1 μm and TEWL by 2.5 gm h was detected by tape stripping and 
evaporimeter. This demonstrates that both methods are suitably sensitive for our purposes 
of detecting changes in skin barrier function. 
Conclusion 
TEWL and tape stripping used in combination provides a powerful and yet simple and 
efficient minimally-invasive method for the characterisation and assessment of skin barrier 
function both in vitro and in vivo and is suitable for the purpose, in our investigations, for 
studying the active ingredient penetration profile of topical formulations and also for 
determination of skin barrier function. 
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Summary 
Background - There are many zinc containing formulations for the treatment of skin 
conditions available on the market today. To formulate a novel zinc containing topical 
product for the treatment of eczema, it is first necessary to investigate the ability of zinc to 
penetrate into the skin and, second, an analytical technique that can quantify the amount 
delivered needs to be established. 
Objectives - To assess the in vitro delivery of zinc into the skin by passive diffusion from 
aqueous solutions of zinc chloride (ZnCl2) and to develop a methodology to quantify the 
amount penetrated into the stratum corneum. 
Method - Aqueous solutions of 5% and 50% w/v zinc chloride (ZnCl2) were delivered to 
porcine abdominal skin by passive diffusion for six hours. The skin was tape stripped and 
the zinc was extracted using 10% acetic acid. Analysis was carried out using atomic 
absorption spectroscopy (AAS). 
Results - The amounts of zinc delivered to the skin from 5% and 50% w/v ZnCl2 solutions 
were 57 ± 21 μg and 489 ± 117 μg (P < 0.0001), respectively. No penetration of zinc was 
observed through the skin into the receptor solution. 
Conclusions - Passive diffusion of zinc into the SC was ten-fold greater from 50% w/v 
ZnCl2 compared to a 5% w/v solution. There was negligible transport of zinc across the 
skin, however, from either solution. AAS proved sufficiently specific, sensitive and 
reliable to assess the performance of zinc containing formulations. 
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Introduction 
Having established a method to characterise and assess the skin barrier function both in 
vitro and in vivo, as previously described in Chapter 2, the next step leading to the 
production of a novel zinc containing formulation is the investigation of zinc delivery to 
the skin in vitro and establishing an analytical method to assess and quantify the amount of 
zinc extracted from skin samples. 
There are a multitude of commercial zinc oxide formulations available on the market 
today.(1) The majority comprise creams or ointments which act as physical barriers to 
protect the skin from contact with irritating substances such as urine in the case of nappy 
rash, and also to prevent the increased loss of water through damaged skin in conditions 
such as eczema and psoriasis.(2-4) In addition to topical preparations, medicated bandages 
containing zinc paste are also available and are used to treat lichenification in psoriasis and 
chronic eczema due to repeated scratching.(1, 5) The formulations contain zinc as the 
active ingredient mostly in the form of zinc oxide with concentrations ranging from 7.5 ­
38 % w/w dispersed in a mixture of waxes, fats and other supposedly beneficial substances 
such as ichthammol, cod-liver or castor oil.(1, 4, 6) However, literature regarding these 
formulations, their efficacy or the penetration of zinc into the skin is scarce. Sunscreens 
represent another, important category of zinc containing formulations used for non-
medicinal purposes.(1, 4) With the exception of sunscreens, the efficiency of zinc delivery 
from these medicinal formulations for the treatment of skin conditions has not been studied 
in depth. 
Zinc is an essential mineral in the body and is a co-factor of more than 300 
metalloenzymes (including alcohol dehydrogenase, angiotensin converting-enzyme and 
alkaline phosphatase) and in excess of 2000 transcription factors. Zinc is acknowledged to 
be essential for the normal development and physiology of humans as it is involved in the 
synthesis, transcription and translation of RNA and DNA.(7-9) After iron, zinc is the 
second most abundant trace element in the body.(9) An average human adult of 65kg (of 
which 7kg is skin) contains about 2.5g zinc, 6% of which is present in the skin.(10, 11) 
The significance of zinc to dermatological health is apparent when, in situations where a 
deficiency occurs due to dietary insufficiency or genetically induced malabsorption from 




epidermolysis bullosa simplex and epidermolytic hyperkeratosis (which causes blistering 
of the skin) occur.(12, 13) Zinc was recognised more than 3000 years ago by the ancient 
Indians and used in Ayurvedic medicine as documented in the Papyrus Ebers as beneficial 
for the skin and was used as a topical treatment for wound healing in the form of zinc 
oxide or calamine.(8, 9) In conditions such as atopic eczema, where premature and 
enhanced desquamation occurs, the incorporation of zinc into a formulation for topical 
application would neutralise excess proteases and aid restoration of the skin barrier.(14, 
15) 
The amount of zinc present in the skin is a testament to its importance to skin health and 
barrier function since it is involved in morphogenesis, and more relevant to this thesis, 
repair and maintenance of the skin barrier.(11) Where a diet is deficient in this mineral, 
dermatological symptoms such as periorificial and acral skin lesions in acrodermatitis 
enteropathica, skin ulcers, xerosis, roughness of the skin, eczema and delayed wound 
healing occur.(8, 10, 12) The importance of zinc to the condition and health of skin is 
evident in (for example) psoriasiform dermatitis (caused by poor absorption of zinc in 
acrodermatitis enteropathica) and chronic leg ulcers, conditions which are successfully 
treated with oral zinc supplements and topical zinc oxide preparations, respectively.(8) 
Furthermore, research has shown that zinc accumulates in wounds inflicted on the back of 
mice indicating its role in repair and healing and the use of zinc supplements increase 
healing rates in damaged tissues.(11, 16) Zinc deficient mice also display delayed wound 
epithelialisation.(11) Another example of the importance of zinc to skin health is 
demonstrated by the apoptosis of human keratinocytes when placed in zinc-deficient 
medium.(13) It is obvious that zinc plays a major role in the health of the skin, however; it 
is well documented that zinc penetration into the skin is limited.(17-21). Since the 
development of a novel zinc containing formulation for the treatment of eczema is 
currently in progress, the penetration of zinc into the skin and an analytical technique for 
its quantification need first to be established. 
In this study, an investigation assessing the percutaneous penetration of zinc in vitro was 
performed using dermatomed abdominal porcine skin in Franz diffusion cells. Zinc 
delivery into the stratum corneum (SC), and across the skin, from 5% and 50% w/v 
aqueous zinc chloride solutions was determined using tape stripping after a six hour 
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treatment and analysis of the samples, post-extraction, was carried out by atomic 
absorption spectroscopy (AAS). 
Materials and Methods 
Materials

Chemicals: Zinc chloride, 99.995 +% purity was purchased from Sigma-Aldrich, Inc. (St. 

Louis, MO, USA). Sodium chloride, disodium hydrogen phosphate, potassium phosphate, 

and potassium chloride were purchased from Acros Organics (Geel, Belgium). Zinc nitrate

®
standard solution was from SpectroSol (BDH Chemicals Ltd., Poole, UK). 
Skin preparation 
Porcine skin obtained from a local piggery (B & J Pigs Ltd., Somerset, UK) was cleaned 
under cold running water and dermatomed to a thickness of approximately 750 μm 
TM
(Zimmer Electric Dermatome, Dover, OH, USA). The pieces of skin were then wrapped 
TM
in Parafilm , placed into a sealed bag and stored in a freezer at -20°C until required. 
In vitro passive diffusion experiments 
A piece of frozen porcine abdominal skin was thoroughly thawed and visually inspected 
for defects and punctures. (Previous studies have shown pig skin to be a well-established 
model for human skin for both in vivo and in vitro studies and that storage at -20 ºC 
generally does not alter percutaneous absorption.)(22, 23) Excess hair was carefully 
trimmed using scissors and the skin was divided into three pieces; control, treated with 5% 
w/v aqueous ZnCl2, and treated with 50% w/v aqueous ZnCl2. The pieces of skin were 
mounted into vertical Franz diffusion cells (PermeGear, Inc., Bethlehem, PA, USA) with 
the external surface, the stratum corneum side, facing the donor chamber (donor volume = 
2
3 ml). The area available for transport was approximately 3 cm . The receptor chambers 
(volume = 7 ml) were filled with phosphate-buffered saline (PBS: 137 mM NaCl, 10 mM 
phosphate, 2.7 mM KCl) at pH 7.4. To verify skin integrity and allow thermal 
equilibration, the cells were inverted and observed for leaks. After 30 minutes the cells 
were returned to the upright position and connected to a syringe pump (“Genie” Kent 
programmable syringe pump, Kent Scientific Corporation, Litchfield, CT, USA). Timing 





donor solutions and covered with Parafilm . The receptor solutions were stirred 
magnetically throughout the experiment. Passive diffusion took place over 6 hours at room 
temperature and 1 ml samples of the receptor solution were collected every hour. For every 
1 ml collected, an equal volume of fresh PBS was delivered by the syringe pump. At the 
end of the experiment, the donor solutions were collected and reserved for analysis. 
Between collection and analysis, the samples were stored at 4ºC. The pieces of skin were 
dismounted from the cells and thoroughly dried using lint-free absorbent tissue before 
TM
being temporarily stored between sheets of Parafilm until the tape stripping procedure. 
A minimum of ten replicates per donor solution was performed and the skin from five 
different pigs was used in the experiments. 
Tape-stripping 
Endogenous zinc (control) and the amounts delivered into the stratum corneum were 
assessed following tape-stripping. After drying, the skin was pinned to a polystyrene board 
and a template with a circular aperture (diameter = 2 cm) was affixed to delineate the area 
to be sampled. Baseline transepidermal water loss (TEWL) was measured (Biox Aquaflux 
AF102, Biox Systems Ltd., London, UK) and the skin was subjected to multidirectional 
sequential tape stripping with adhesive tapes (Scotch No. 845 book tape. 3M, St. Paul, 
MN, USA) that had been previously weighed using a 0.1 μg precision balance (Sartorius 
AG SE-2F semi-microbalance, Sartorius AG, Göttingen, Germany). TEWL measurements 
were made after every other tape strip and monitored as an indicator of total SC removal 
-2 -1
(when TEWL ~100 g.m h ). 
Sample Analysis 
After tape-stripping, the tapes were re-weighed to allow the mass and thickness of SC 
removed to be calculated. The zinc was extracted from the tapes by shaking overnight 
®
(IKA HS 260 Basic shaker, IKA Werke GmbH & Co., KG, Germany) in 10% acetic acid. 
Prior to analysis, all samples were appropriately diluted with 10% acetic acid to facilitate 
analysis by atomic absorption spectrometry (AAS) (Varian AA-275, Varian, Inc., Oxford, 
UK). The instrument was calibrated using 0.5, 1.0 and 2.0 ppm zinc nitrate calibration 
standards and the samples were analysed at 213.9 nm with a spectral bandwidth of 1 nm. 
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2
Fig. 1 Calibration curve for zinc standards using the AAS. Readings were obtained in triplicate. (r = 0.9935) 
To enable an estimation of mass balance, the original donor solutions of 5% w/v and 50% 
w/v aqueous ZnCl2 (prior to passive diffusion experiments) were also diluted and analysed. 
® TMAll solutions were prepared with deionised water, 18.2 MΩ-cm (NANOpure DIamond
Life Science (UV/UF) Ultrapure Water System, Barnstead International, Dubuque, Iowa, 
USA). 
Data Analysis and Statistics 
SC thicknesses were calculated from the TEWL measurements recorded during tape 
stripping using a modified form of Fick‟s 1st Law of diffusion (Eqn. 1).(24) 
K · ΔC · D 
J  = (Eqn. 1) 
H 
Because TEWL changes only very slightly (if at all) during the removal of the first one or 
two tape strips, a baseline-corrected, non-linear model (Eqn. 2) has been proposed to fit 
TEWL data recorded during SC tape stripping.(25) 
K · D · ΔC 
TEWLx = B  + 
(Eqn. 2) 
H - x 
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Where TEWLx represents the flux of water across the stratum corneum the thickness of 
which has been reduced from H to (H – x) by stripping, K is the stratum corneum -viable 
epidermis partition coefficient of water (0.06), D is the diffusivity of water within the SC, 
-3ΔC is the concentration gradient of water across the stratum corneum (~ 1g/cm ), and H is 
the total stratum corneum thickness. (Eqn. 2).(24, 26) In this equation, K·D·ΔC is 
assumed constant (30) for any volunteer at any time.(25) This method enables all data to be 
taken into account and the stratum corneum thickness is calculated using non-linear 
regression (Fig. 2). In order to be able to make comparisons between individual pieces of 
skin, which have different stratum corneum thickness of course, all data were evaluated as 
a function of normalised position within the stratum corneum as previously reported and 
discussed in detail (24, 25). 
Normality tests, non-linear regression and statistical analyses were performed using 
®
GraphPad Prism 4.00 software (Graph Pad Software Inc., San Diego, CA, USA). 
Statistical significance between multiple data sets was determined via one-way ANOVA. 
The confidence interval was adjusted to 95% and the significance level was set at P < 0.05. 
Outliers, determined by Grubb‟s test (http://www.graphpad.com/quickcalcs/index.cfm), 
were removed from data analysis. 
Fig. 2 An illustrative graph showing non-linear regression of the change in TEWL as a function of the 
amount of stratum corneum removed using the modified form of Fick‟s 1st Law of diffusion (25) . In this 
-2 -1 -1 -1
example, for the fitting procedure, initial values of B, K.D.ΔC, and H were 14.4 gm h , 30 gcm h , and 7.4 
-2 -1μm, respectively. The values for best fits for B, K.D.ΔC, and H were calculated to be 6.3 gm h , 61.8 and 
8.3 μm, respectively. 
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Results 
The change in TEWL as a function of tape-stripping from the skin samples that were used 
for the control and zinc uptake experiments was quite consistent. The fitted values of B, 
K·D·ΔC and H (according to Eqn. 2) are in Table 1, and reveal no significant differences 
between any of the derived parameters. 
Table 1 Fitted values (mean ± SD; n = 10 for controls and n = 11 for 5% and 50% ZnCl2) of B, K·D·ΔC and 










Total SC thickness, 
H (µm)
Control 5.1 ± 9.0 164 ± 87 12.4 ± 4.2
5% ZnCl2 -4.0 ± 12.5 287 ± 198 13.4 ± 4.1
50% ZnCl2 5.8 ± 5.3 87 ± 61 13.7 ± 1.9
Total zinc recoveries for control, 5% and 50% w/v ZnCl2 treatments were 2.8 ± 0.69 μg, 
45.2 ± 4.05 mg, and 385 ± 60.6 mg, respectively (Table 2). The latter two values 
correspond to 85% of the applied amounts. Apparent losses of approximately 15% were 
most likely the result of residual solution on glassware and that remaining on the surface of 
the skin which was removed by wiping prior to tape stripping. 
Table 2 Zinc uptake results into (mean ± SD; n = 10 for controls, n = 11 for zinc chloride treatments and 
through skin after treatment with either 5% or 50% w/v ZnCl2 solution; control, untreated skin, results are 
included 
Treatment 






Total Zn recovered Zn in donor 




Post-diffusion μg % w/v 
Control 1.0 ± 0.6 1.8 ± 0.7 0 2.8 ± 0.69 0.0003 0 
5% ZnCl2 57 ± 21 2.9 ± 1.2 45100 45160 ± 4049 4.5 5.29 
50% ZnCl2 489 ± 117 2.7 ± 1.5 385000 385492 ± 60641 38.5 45.35 
Ratio: 50% : 5% 8.58:1 0.93:1 8.54:1 8.54:1 8.56:1 8.57:1 
Figure 3 shows zinc penetration into the SC from solutions of 5% and 50% w/v aqueous 
zinc chloride solutions. In the zinc control experiments, where the skin was treated with 
de-ionised water that contained non-detectable amounts of zinc, the endogenous levels of 
zinc found in the stratum corneum were very low. Although it is difficult to view from the 
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graphs in Fig. 3, the lower stratum corneum layers of skin treated with 5% w/v ZnCl2 
contained seven-times more zinc than the endogenous levels. 
(a) (b) 
Fig. 3 The uptake of zinc into the stratum corneum expressed as either (a) the amount of zinc per sample, or 
(b) amount of zinc per unit weight of stratum corneum, as a function of normalised stratum corneum depth. 
There is a clear distinction observed between the delivery from 5% and, 50% w/v ZnCl2 solutions and from 
the zinc-free controls. Endogenous zinc levels were very low. 
Transformation of the amounts of zinc per sample (Fig. 3a) into the quantity of zinc per 
unit mass of stratum corneum, plotted as a function of % stratum corneum depth, reveals a 
clear clustering of the treatment groups (Fig. 3b) and that zinc uptake into the stratum 
corneum from the 50% w/v solution is considerably higher than that from the lower 
concentration solution. Semi-logarithmic graphs of the same data further delineate the 
differences perceived (Fig. 4). 
(a) (b) 
Fig. 4 Penetration profiles of zinc delivered to the SC in vitro expressed in terms of (a) the amount of zinc per 
tape strip (μg), and (b) the quantity of zinc per unit of mass of stratum corneum. 
49




















































Delivery of Zinc to the Skin - Establishment of an Analytical Method 
When the results are presented in terms of the cumulative amounts of zinc delivered to the 
stratum corneum, a similar differentiation between treatments is clear (Fig. 5) The 
cumulative amounts of zinc recovered in the control stratum corneum and in skin treated 
with 5% w/v and 50% w/v ZnCl2 ranged from 0.24 - 1.9 µg, 33 - 96 µg and 360 - 712 µg, 
respectively.  
(a) (b) 
Fig. 5 Cumulative amounts of zinc in the SC as a function of depth into the tissue showing a clear separation 
between the different treatment groups. 
The corresponding mean values (± SD) were 1.0 ± 0.6 µg (n = 10), 57 ± 21 µg and, 489 ± 
117 µg (n = 11 for each zinc chloride treatment group) (Fig. 6). The absorption of zinc into 
the SC from a 50% w/v ZnCl2 solution was approximately an order of magnitude greater 
than that from a 5% w/v solution. Overall, uptake represented is approximately 0.04% of 
the applied amount. The data demonstrate that zinc permeation into the stratum corneum 
was proportional to ZnCl2 concentration and that zinc ions were able to penetrate into the 
SC albeit with rather poor efficiency. A one-way ANOVA confirmed that there were 
significant differences between treatment groups with P < 0.0001. 
50







1.0 g   0.6
57 g   21






























































1.8 g   0.7
2.9 g   1.2

























Fig. 6 Mean values (± SD) of cumulative zinc in the SC show significant differences between treatment 
groups (P < 0.0001) (n = 10 for control, and n = 11 for 5% and 50% w/v ZnCl2 solutions). 
The appearance of zinc in the receptor solution of the in vitro diffusion cell experiments as 
a function of time following topical application of either water (control) or 5% and 50% 
w/v ZnCl2 solutions is shown in Fig. 7a. Total „delivery‟ of zinc over 6 hours is in Fig. 7b. 
The amounts determined (mean ± SD) were: control, 1.8 ± 0.7 μg (range 1-2 μg; n = 4), 
5% w/v ZnCl2, 2.9 ± 1.2 μg (range 2-5 μg; n = 7); 50% w/v ZnCl2 2.7 ± 1.5 μg (range 1-4 
μg; n = 8). A one-way ANOVA indicated no significant difference between these results (P 
= 0.3551).  
(a) (b) 
Fig. 7a Hourly sampling of the receptor compartment showed only low levels of zinc. Fig. 7b No statistical 
significance was observed in zinc content of receptor solutions between treatment groups, P = 0.3351. 
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Discussion 
The skin uptake experiments performed here using 5% and 50% w/v ZnCl2 show that zinc 
ions permeate into the stratum corneum in a manner proportional to the applied 
concentration: mean cumulative values were 57 ± 21 µg and 489 ± 117 µg, respectively, 
while endogenous zinc in the stratum corneum was only 1.0 ± 0.6 µg. Despite the 
significant differences between treatment groups (P < 0.0001), the absorption of zinc was 
low, only approximately 0.04%, reflecting the greater affinity of ZnCl2 for the aqueous 
solution (and its high solubility therein) in which it was applied to the lipophilic stratum 
corneum. Analysis of receptor solutions determined the degree to which zinc penetrated 
through the barrier. Topical application of 5% and 50% w/v ZnCl2 solutions resulted in no 
apparent penetration of zinc ions through the skin. The small quantities of zinc detected 
almost certainly originated from the skin itself as the levels detected after the zinc 
treatments overlapped with those from the controls. These results agree with those from an 
earlier study assessing the absorption of microfine metallic oxides (zinc and titanium) 
through porcine skin in vitro, and which showed that neither element was able to penetrate 
across the barrier.(17) Although in vitro experiments can never be interpreted completely 
unambiguously, porcine skin is a well-recognised model for the human counterpart, and 
the excision and storage protocol employed here have been shown to have a negligible 
effect on barrier function.(27) 
Overall, therefore, the data from this investigation demonstrate that it is possible to deliver 
zinc into the stratum corneum and that, at least for high concentration ZnCl2 solutions, the 
uptake is proportional to concentration. The efficiency of the process, however, is low and 
the need for a more practical formulation providing improved bioavailability is clear. 
These conclusions are possible because of the sensitivity and robustness of the atomic 
absorption assay for zinc in the stratum corneum and donor/receptor samples analysed. The 
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Percutaneous Penetration of Zinc from Commercial Formulations 
Summary 
Background - Many topical zinc preparations are available on the market for the treatment 
of dermatological conditions. Their purpose, however, is to act as a physical, mechanical 
barrier that resides on top of the skin to protect it from contact with irritants such as faeces 
or urine in the case of nappy rash (diaper dermatitis). 
Objectives - To investigate the in vitro delivery of zinc from three commercial 
®
formulations; zinc and castor oil cream (7.5% w/w ZnO), Sudocrem (15.25% w/w ZnO) 
®
and Morhulin (38% w/w ZnO) currently available on the market 
Methods - Porcine abdominal skin was subjected to passive diffusion with an excess of 
formulation for six hours in a Franz diffusion cell. Alternate transepidermal water loss 
measurements and tape stripping was carried out on the skin followed by the extraction of 
zinc using acetic acid and quantification by inductively coupled plasma-atomic emission 
spectroscopy (ICP-AES). The control consisted of passive diffusion with deionised water. 
Results - Of the three commercial formulations tested, the lowest and highest uptake of 
zinc into the stratum corneum was from zinc and castor oil cream (8 ± 6 µg) and 
®
Morhulin ointment (58 ± 35 µg), respectively. Amounts of zinc measured from the 
controls were low, 0.9 µg ± 0.5. One-way ANOVA revealed a significant difference of P < 
0.0001 between treatment groups. Amounts of zinc measured in the receptor solutions 
were low and no significant difference was detected between treatments with P = 0.16. 
®
Conclusions - The uptake of zinc into the stratum corneum from Morhulin ointment was 
highest. Amounts of zinc delivered to the skin appeared to be dependent on the applied 
dose of zinc oxide. However, considering the concentrations of zinc contained in the 
formulations, uptake of zinc into the skin is low. This supports the need for the 
development of a novel topical formulation to aid reparation of the damaged skin barrier in 
atopic eczema. Further, no penetration of zinc into the receptor solution indicates a 
negligible risk of systemic toxicity from the percutaneous absorption of these formulations. 
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Current treatments for eczema mainly revolve around emollients, topical corticosteroids, 
topical calcineurin inhibitors, antipruritics and antihistamines.(1, 2) Emollients are 
prescribed first and foremost in the treatment of eczema to aid rehydration of the xerotic 
skin barrier.(3, 4) Emollient therapy helps control flare-ups of eczema and is expected to 
be used long term to keep the skin moist and supple. They should be used at least twice a 
day and on a more regular basis on exposed areas such as the hands and face.(2-4) 
However, emollient therapy only serves three purposes; (i) rehydration of the stratum 
corneum to reduce dryness and therefore, improve flexibility, softness and decrease the 
development of fissures in the skin, (ii) trapping moisture in the skin and thus reducing 
water loss by creating a lipid film over the surface, and (iii) provision of limited protection 
against assault from external irritants.(3) 
Topical corticosteroids are also commonly used to control flare-ups in eczema.(1, 2, 4-6) 
Though they decrease inflammation and relieve pruritus (which reduces the frequency of 
scratching in patients), long term use is not advised due to well recognised side effects.(2, 
6-8). Topical gluococorticoids, for example, betamethasone 17-valerate, prednicarbate and 
mometasone furoate, have been well known to cause skin atrophy.(8, 9) Other side-effects 
include acne, striae, ulcerations and even steroid rebound or addiction.(7) Topical 
calcineurin inhibitors such as cyclosporin, tacrolimus and pimecrolimus control the disease 
state by suppressing the immune response in eczema.(2, 6, 10) However, adverse effects 
include, but are not limited to, increased permeability of the skin barrier and suppress T-
lymphocyte responses which may lead to increased rates of infection and malignancies.(4, 
6, 11, 12) Antipruritics and antihistamines offer sedative affects and also control itching 
and inflammation which lead to help relieve discomfort caused by irritants and allergens 
that pass through the skin barrier.(1, 2, 6) 
The majority of treatments described here offer relief of symptoms only after the 
manifestations have already caused considerable suffering and discomfort for both the 
patient and their families. Their intended use is to control exacerbations of lesions, itch and 
soreness in affected areas. Emollients are useful in providing additional moisture, 
flexibility to the skin and also relieving sensations of tightness. However, these treatments 
are fraught with side-effects and do not address the problem that exists in eczema which is 
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the defective skin barrier. Minute cracks in the stratum corneum allow the facile influx of 
irritants and allergens into and through the skin to cause discomfort which lead to 
scratching and ultimately, the development of eczematous lesions.(5, 13-15) To prevent or 
decrease episodes of flare-ups in the disease would require a means to repair the skin 
barrier and not just to treat the symptoms once they have manifested. One method of doing 
so would be to deliver zinc to the skin barrier to aid reparation and restoration of its 
integrity. As mentioned briefly in Chapter 2, deficiencies in zinc are manifested as 
dermatological disorders such as skin lesions (observed in eczema), epidermolysis bullosa 
simplex and delays in the healing of wounds.(16, 17) Further, research has revealed that 
zinc accumulates in wounds during healing and that rates of healing in damaged tissues are 
increased after the administration of zinc supplements.(18, 19) Since evidence support the 
fact that zinc plays such an essential role in the skin during epithelialisation and 
maintenance, it would be logical to develop a novel topical formulation for the treatment of 
the skin barrier in eczema. Considering that there are already many commercial topical 
zinc preparations available on the market today, and also the fact that zinc oxide (the active 
ingredients in these creams and ointments) is notoriously insoluble (0.16 mg/100 ml 
water), it would be pertinent to test the uptake of zinc from these products and eventually 
compare their performance with that of novel formulations prepared during the course of 
this thesis.(20) 
For this study, three topical zinc preparations were purchased; zinc and castor oil 
® ®
(Thornton and Ross Ltd.), Sudocrem (Forest Tosara Ltd.) and Morhulin ointment 
(Actavis UK Ltd.) and subjected to passive diffusion in vitro on porcine abdominal skin 
followed by tape stripping. The zinc content of each tape strip was quantified by 




Materials and Methods 
Materials 
Chemicals: Sodium chloride, disodium hydrogen phosphate, potassium phosphate, and 
potassium chloride were purchased from Acros Organics (Belgium). Zinc and Castor oil 
cream BP (zinc oxide 7.5% w/w, virgin castor oil 50.0% w/w, cetostearyl alcohol, white 
beeswax (E901), arachis oil) was purchased from Thornton & Ross Ltd. (Huddersfield, 
®
UK), Morhulin Ointment (zinc oxide BP 38% w/w, cod-liver oil BP 11.4% w/w, liquid 
paraffin BP, yellow soft paraffin BP, lanolin anhydrous BP, castor oil BP, diluted sodium 
®
hypochlorite solution) from Actavis UK Ltd (Devon, England, UK) and Sudocrem (zinc 
oxide Ph.Eur. 15.25%, benzyl alcohol BP 0.39%, benzyl benzoate BP 1.01%, benzyl 
cinnamate 0.15%, lanolin (hypoallergenic) 4% w/w, purified water, liquid paraffin, 
paraffin wax, beeswax, microcrystalline wax, sodium benzoate, linalyl acetate, propylene 
glycol, citric acid, butylated hydroxyanisole, sorbitan sequioleate, lavender fragrance) from 
Forest Tosara Ltd. (Dublin). 
Skin preparation 
Porcine skin obtained from a local piggery (B & J Pigs Ltd., Somerset, UK) was cleaned 
under cold running water and dermatomed to a thickness of approximately 750 μm 
TM
(Zimmer Electric Dermatome, Dover, OH, USA). The pieces of skin were then wrapped 
TM
in Parafilm , placed into a sealed bag and stored in a freezer at -20°C until required. 
Experimental Procedure 
Frozen porcine abdominal skin was thawed and visually inspected for defects and 
punctures. Excess hair was carefully trimmed and the skin was rinsed under de-ionised 
water then mounted into vertical Franz diffusion cells (PermeGear, Inc., Bethlehem, PA, 
USA) with the external SC surface facing the donor chamber. The area available for 
2
transport was approximately 3 cm . The receptor chambers (volume ~ 6 ml) were filled 
with phosphate-buffered saline (PBS: 137 mM NaCl, 10 mM phosphate, 2.7 mM KCl) at 
pH 7.4. To verify skin integrity and allow thermal equilibration, the cells were inverted and 
observed for leaks. After 30 minutes the cells were returned to the upright position and 
connected to a water bath set at 32 ºC and a syringe pump (“Genie” Kent programmable 
syringe pump, Kent Scientific Corporation, Litchfield, CT, USA). Thermal equilibration 
took place whilst the formulation was being applied and initiation of the experiment began 
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after application of the formulation (using a gloved cotton bud) was complete and the 
TM
donor compartment covered with Parafilm . The receptor solution was stirred 
magnetically. 1 ml samples were collected and replaced with fresh buffer at 60 minute 
intervals over six hours. Following passive diffusion, the skin was removed from the cell 
and the cream was gently wiped off using a dry paper towel and three isopropyl alcohol 
TM
wipes and stored between Parafilm sheets until the next procedure. For tape stripping, 
the skin was pinned to a polystyrene board and a circular template was attached to 
demarcate the boundary. Baseline transepidermal water loss (TEWL) was measured (Biox 
Aquaflux AF102, Biox Systems Ltd., London, UK) and the skin was subjected to 
multidirectional sequential tape stripping with adhesive tapes (Scotch No. 845 book tape. 
3M, St. Paul, MN, USA) that had been previously weighed using a 0.1 μg precision 
balance (Sartorius AG SE-2F semi-microbalance, Sartorius AG, Göttingen, Germany) and 
electrically discharged (anti-static device, Eltex, Germany). TEWL measurements were 
made after every other tape strip and monitored as an indicator of total SC removal (when 
-2 -1
TEWL ~ 100 gm h ). The procedure was carried out using zinc and castor oil cream (7.5 
® ®
% ZnO), Sudocrem (15.25% ZnO) and Morhulin (38% ZnO). Mean doses applied were 
0.49 ± 0.04 g. For the controls, deionised water was used in place of the cream. 
Sample Analysis by Inductively Coupled Plasma-Atomic Emission Spectroscopy 
After tape-stripping, the tapes were re-weighed to allow the mass and thickness of SC 
removed to be calculated. The zinc was extracted from the tapes by shaking overnight 
®
(IKA HS 260 Basic shaker, IKA Werke GmbH & Co., KG, Germany) in 10% acetic acid. 
Prior to analysis, all samples were appropriately diluted with 10% acetic acid to facilitate 
analysis using an inductively coupled plasma sequential atomic emission spectrometer 
(ICP- AES) (JY Horiba Ultima, Japan) fitted with a Burgener T2100 Nebulizer and JY 
Horiba AS421 autosampler set at a wavelength of 213.9 nm. Calibration standards were 
prepared from dilution of 1000 ppm Primar F Zinc Standard from Fisher Scientific Ltd. 
UK (Loughborough, Leicestershire, UK). All solutions were prepared with deionised 
® TMwater, 18.2 MΩ-cm (NANOpure DIamond Life Science (UV/UF) Ultrapure Water 
System, Barnstead International Dubuque, Iowa, USA). 
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Data Analysis and Statistics 
SC thicknesses were calculated from the TEWL measurements recorded during tape 
stripping using a modified form of Fick’s 1st Law of diffusion as described previously. 
Normality tests, non-linear regression and statistical analyses were performed using 
®
GraphPad Prism 4.00 software (Graph Pad Software Inc., San Diego, CA, USA). 
Statistical significance between multiple data sets was determined via one-way ANOVA. 
The confidence interval was adjusted to 95% and the significance level was set at P < 0.05. 
Outliers, determined by Grubb’s test (http://www.graphpad.com/quickcalcs/index.cfm), 
were removed from data analysis. 
Results 
The penetration profiles of zinc delivered from the three commercial preparations as a 
function of normalised stratum corneum depth are shown in Fig.1. Delivery of zinc from 
®
the Morhulin ointment (38% w/w ZnO) is clearly the highest (blue). The zinc and castor 
oil cream (7.5% w/w ZnO) (green) performed less well and overlaps with the controls 
(open circles). No clear segregation between treatment groups was observed. 
a) b) 
Fig. 1 The amounts of zinc per tape strip is expressed as a function of normalised stratum corneum depth 
showing endogenous zinc from the controls (untreated) to be lowest and that from Morhulin
® 
the highest. 
Fig. 2 shows the transformation of the amounts of zinc per sample into the quantity per 
unit mass of stratum corneum plotted as a function of normalised depth 
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a) b) 
Fig. 2 The uptake of zinc into the stratum corneum expressed as amount of zinc per unit weight of stratum 
corneum, as a function of normalised stratum corneum depth. Zinc extracted from the controls (untreated) 
and Morhulin
® 
is clearly seen as the lowest and highest amounts, respectively. 
®
The graphs clearly show the Morhulin (blue) and control data (untreated) (open circles) 
begin to separate from other treatments (Fig. 2) with the former and latter being the lowest 
and highest amounts of zinc contained in the stratum corneum, respectively. 
Expressing the cumulative amounts of zinc delivered into the stratum corneum as a 
function of stratum corneum depth is shown in Fig. 3. The control group (open circles) is 
®
almost entirely separate from the treated data (Fig. 3b). This is also true of the Morhulin
®
data (blue). Zinc and castor oil cream (green) and Sudocrem (red) data are obviously 
overlapped with no differentiation into their respectively treatment groups. The highest 
amount of zinc extracted from skin treated with Morhulin® was approximately 100-times 
of that from endogenous sources. 
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Fig. 3 Cumulative amounts of zinc in the stratum corneum as a function of depth into the tissue showing zinc 
extracted from the control and Morhulin
® 
treated skin to be almost entirely separated from the other 
treatment groups. 
When represented as a bar graph, cumulative amounts of zinc in the stratum corneum 
(mean ± SD) can be seen to increase with the applied dose of formulation applied, i.e., zinc 
uptake into the stratum corneum increased with the applied dose (Fig. 4). Statistical 
analyses using one-way ANOVA detected a significant difference between treatment 
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Percutaneous Penetration of Zinc from Commercial Formulations 
Fig. 4 Cumulative amounts of zinc extracted from the stratum corneum following six hours passive diffusion 
with commercial formulations. The control was carried out using deionised water. The amounts of zinc 
extracted from the stratum corneum appeared to increase with concentration applied. One-way ANOVA 
revealed a significant difference between treatment groups (P < 0.0001) (n = 11 for control, n = 6 for Zinc & 
Amounts of zinc detected for the control, Zinc and castor oil cream, Sudocrem and 
castor oil cream and Sudocrem
® 
and n = 13 for Morhulin
®
). 
For the receptor solutions, overlap between treatment groups was observed (Fig. 5). 
® 
®
Morhulin were 3.51 ± 1.02 μg, 4.13 ± 0.59 μg, 4.49 ± 1.13 μg and 4.29 ± 0.80 μg, 
respectively. One-way ANOVA did not reveal a significant difference between treatment 
groups (P = 0.16). 
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Fig. 5 Samples taken every hour from the receptor solution revealed only low amounts of zinc. No significant 
difference was observed in zinc content receptor solutions between treatment groups (P = 0.16). 
Discussion 
This study was carried out to investigate the uptake of zinc into the stratum corneum from 
®
commercially available formulations, zinc and castor oil (7.5% ZnO), Sudocrem (15.25 % 
®
ZnO) and Morhulin (38% ZnO) and to compare these results with those from novel 
formulations described in Chapter 5. 
®
The results clearly show that zinc uptake from Morhulin was the highest followed by 
®
Sudocrem and zinc and castor oil where the amounts of zinc extracted from the stratum 
corneum were 57.9 ± 35.4 μg, 14.15 ± 6.92 μg and 8.47 ± 5.67 μg, respectively. Only 0.85 
± 0.53 μg was extracted from the control. No clear segregation between treatment groups 
was observed (Fig.3). Despite the overlapping of treatments, a significant difference was 
detected between groups (P < 0.0001). The uptake of zinc into the stratum corneum from 
®
zinc and castor oil cream and Sudocrem appeared to be proportional to zinc oxide 
®
concentration. Although zinc uptake from Morhulin ointment was the most efficient, it 
should be noted that the concentration of zinc oxide in the formulation was highest at 38% 
®
w/w. However, while the concentration of zinc oxide in Morhulin ointment is 
®
approximately 2.5 times that of Sudocrem , but the difference in uptake between the 
formulations was four-fold. The amount zinc penetrated into the stratum corneum can be 
misleading because only when the data is represented in terms of percentage of the applied 
dose (i.e., normalisation) can comparisons in efficiency be made between formulations. 
The uptake of zinc into the stratum corneum presented as such for zinc and castor oil, 
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® ®
Sudocrem and Morhulin was 0.02%, 0.02% and 0.03%, respectively. The penetration of 
5% and 50% w/v zinc chloride in Chapter 3 was approximately 0.04%. 
When comparing absolute amounts of zinc penetrated into the stratum corneum from the 
creams with that of the zinc chloride solutions of approximately the same zinc 
concentration, it is apparent that latter delivers considerably more zinc than the former. A 
plausible explanation for this difference can be attributed to the immense difference in 
solubilities between the zinc oxide (0.14 mg/100 ml) contained in the semi-solid 
preparations and the aqueous zinc chloride solution (432 g/100 ml). (20, 21) 
For the receptor solutions, zinc contents of the formulations were similar to that of the 
controls. Overlapping of treatment groups was observed (Fig. 5) and no significant 
difference was detected between treatments (P = 0.16). 
In conclusion, penetration of zinc from commercial formulations was similar from 
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Percutaneous Penetration of Zinc from Novel Formulations 
Summary 
Background - The management and treatment for eczema routinely consists of a 
moisturising regime, the application of corticosteroids, anti-histamine, and if needed, in 
severe cases, immunosuppressive therapy and oral antibiotics. However, these drugs only 
treat the symptoms of eczema but not the underlying cause of the flare-ups: the 
compromised skin barrier. Therefore, the development of a novel topically applied 
formulation is in progress to aid reparation of the stratum corneum. 
Objectives - To assess the delivery of zinc from two novel formulations in vitro, in porcine 
abdominal skin. 
Method - Porcine skin was treated with either a 1% w/w zinc lactate cream or a 2% w/v 
zinc lactate formulation for six hours in a flow-through Franz diffusion cell. Following 
passive diffusion, the skin was tape stripped and the zinc was extracted from these samples 
using 10% acetic acid. Inductively coupled plasma-atomic emission spectroscopy (ICP­
AES) was used to quantify the amount of zinc extracted from each tape strip. 
Results - The uptake of zinc into the stratum corneum from the 1% w/w zinc lactate test 
cream and from the 2% w/v zinc lactate formulation was 4.99 µg ± 1.59 and 2.58 µg ± 
1.93, respectively. Untreated SC contained only 0.83 µg ± 0.59 of endogenous zinc. A one-
way ANOVA revealed a significant difference between these values (P = 0.0001). The 
amounts of zinc detected in the receptor solutions of the diffusion cells following treatment 
with 1% w/w zinc lactate cream, 2% w/v zinc lactate formulation and deionised water were 
1.74 µg ± 0.6 and 1.52 µg ± 0.5 and 1.39 µg ± 0.3, respectively. No significant difference 
was found between these results (P = 0.43). 
Conclusions - Uptake of zinc into the stratum corneum from 1% w/w zinc lactate test 
cream was approximately twice that from the 2% w/v zinc lactate formulation. No zinc 
penetration greater than background into the receptor solutions suggests that the novel 
formulations pose little toxicity risk 
Keywords: Eczema, topical formulation, zinc lactate, tape-stripping, atomic absorption 
spectroscopy, passive diffusion. 
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Introduction 
The skin barrier in dermatological diseases such as eczema and psoriasis is compromised 
due to genetic and environmental factors.(1-4) The genetic aspect dictates the condition of 
the skin barrier and the predisposition to the development of eczema. Genetic mutations 
linked to the disease cause an increase in protease activity and a decreased production of 
intercellular lipid lamellae.(1, 5) These two factors contribute to the premature and facile 
shedding of corneocytes from the skin causing the barrier to breakdown. In normal, healthy 
skin, proteases and protease inhibitors work in collaboration in the regeneration and 
reparation of the skin in homeostasis. In the stratum corneum of healthy skin, low levels of 
skin proteases cause desquamation of corneocytes at the outer surface. The process is 
controlled by protease inhibitors that help maintain skin thickness and ensure that only the 
outer layers are shed.(1) However, in eczema, upregulation of proteases causes premature 
desquamation to occur and the generation of replacement corneocytes cannot keep up to 
maintain a constant thickness of the skin barrier. As a consequence the stratum corneum is 
thinner and more fragile than that of healthy individuals. Intercellular lipid lamellae have 
two major roles in the in the structure of the stratum corneum; they act to hold corneocytes 
together and are responsible for keeping the skin barrier intact and impermeable to the 
penetration of external irritating agents.(6) In eczema, the production of lipid lamellae is 
disrupted, undermining the integrity of the stratum corneum and facilitating thereby the 
influx of irritants and allergen into and through the skin via cracks and fissures.(7) The 
result is hypersensitivity to substances that are normally innocuous to healthy individuals. 
Irritation causes the patient to scratch the affected areas leading to the formation of 
eczematous lesions. Disruption in the generation of intercellular lipid is also related to the 
production of natural moisturising factor (NMF) that keeps the skin soft and flexible and 
helps maintain skin barrier integrity.(8) NMF holds water in the stratum corneum, and 
helps to maintain tight junctions between corneocytes.(9) When the intercellular lipid 
lamellae are disorganised, NMF is reduced and the skin is xerotic and more prone to 
developing fissures. 
While genetic mutations predispose an individual to eczema, environmental factors 
increase the likelihood of symptoms being manifest; for example, low humidity, central 
heating and exposure to a large number of chemicals and foods are known to exacerbate 




(S.aureus) (which is not part of the normal flora of the skin), house-dust mites, and pet 
dander also contribute to the accelerated breakdown of the skin barrier.(1, 11-14) Other 
causative factors include washing with hard water, and most importantly, the use of 
detergents.(1) Sodium lauryl sulphate (SLS) is one of the most commonly used detergents 
at present and is found in a vast number of personal hygiene products, from toothpaste to 
shampoo to shower gels and soaps.(15). The use of detergents has been shown to be the 
most common cause of eczematous flare-ups.(1) In addition, recent research has shown 
that the application of Aqueous Cream BP, which contains ~1% w/w SLS, on healthy skin 
in vivo decreases skin thickness and increases transepidermal water loss.(16) The natural 
pH of skin is acidic („acid mantle‟).(6) However, increases in skin pH caused by contact 
with detergents have been reported.(1) Higher skin pH is known to further drive premature 
desquamation since the activity of skin proteases is optimised in more alkaline conditions. 
Studies have also shown that when exposed to higher pH, skin barrier function and stratum 
corneum integrity are affected.(17, 18) 
Taking into consideration both genetic and environmental factors that affect the condition 
of the stratum corneum, it would be logical to treat the impaired barrier to prevent the 
influx of irritants and allergens instead of treating the symptoms that arise as a result since 
current treatments for eczema revolve around an emollient regimen and application of 
various corticosteroid creams (which, when used excessively, cause skin atrophy in 
addition to other unwanted adverse effects).(19-25) 
A new formulation that proposes to aid reparation of the defective skin barrier in eczema 
has been developed. The novel formulation containing zinc lactate is anticipated to be 
beneficial in three ways. Firstly, the vehicle, a water in oil emulsion, would help alleviate 
the dryness experienced in eczema by providing water to rehydrate the skin, and oil to 
retard further water loss. Secondly, zinc lactate in the formulation should reduce premature 
desquamation of the stratum corneum by neutralising excess proteases. Significant pieces 
of research have shown that zinc has the ability to inhibit stratum corneum chymotryptic 
enzyme (SCCE or kallikrein 7) and stratum corneum tryptic enzyme (SCTE or kallikrein 
5), the main proteases that are responsible for premature desquamation when over 
expressed in eczema.(26, 27) Zinc is also a known beneficial trace element in the treatment 
of wounds. Research has shown that topical application of zinc was more effective in 
promoting the healing of wounds than oral zinc supplements (28-30). Previous studies 
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have also shown that zinc oxide decreased the attachment of S. aureus to plastic tissue-
culture coverslips.(31) Thirdly, the formulation is approximately pH 4.5. In theory, the 
acidity should help restore the natural pH of skin (between 4.5 and 6) and decrease skin 
protease activity which is at an optimum at higher, more alkaline pH as experienced in 
eczema. Increased protease activity is known to alter skin barrier function, stratum 
corneum integrity and cause the degradation of lipid processing enzymes.(17) A decrease 
in skin pH also reduces skin colonisation of S. aureus because the production of 
sphingosine, a natural antimicrobial agent, occurs at low pH. This should also reduce 
premature desquamation since S.aureus is a known secondary protease.(32, 33) Further, it 
has been reported that when skin pH is below 5, the colonisation of S. Aureus is suppressed 
whereas higher pH promotes growth.(34, 35) Hence, lactic acid in the new formulation 
should help reduce skin inflammation and infection related to the increased presence of S. 
aureus.(35) Moreover, a lower skin surface pH is correlated to decreased scaling and 
higher hydration.(35) 
Thus, in this chapter, the penetration of zinc from a novel prototype (2% w/v zinc lactate 
solution) and semi-solid 1% w/w zinc lactate cream formulation will be assessed. 
Materials and Methods 
Materials 
Chemicals: Sodium chloride, disodium hydrogen phosphate, potassium phosphate, and 
potassium chloride were purchased from Acros Organics (Belgium). Zinc oxide (puriss 
grade), glycerol (BP, EP, JP, USP) and DL-lactic acid (Ph.Eur, BP and USP) were all 
purchased from Sigma-Aldrich (Steinheim, Germany), 
Skin preparation 
Porcine skin obtained from a local piggery (B & J Pigs Ltd., Somerset, UK) was cleaned 
under cold running water and dermatomed to a thickness of approximately 750 μm 
TM
(Zimmer Electric Dermatome, Dover, OH, USA). The pieces of skin were then wrapped 
TM




Zinc Lactate Prototype: Zinc oxide and lactic acid (1:2 molar ratio) were dissolved in 
20:80% v/v glycerol/water (gly/H2O) to create a 2% w/v zinc lactate formulation at pH 4.5 
Zinc Lactate Test Formulation: 1% w/w zinc lactate cream from York Pharma Plc. 
Experimental Procedure 
Frozen porcine abdominal skin was thawed and visually inspected for defects and 
punctures. Excess hair was carefully trimmed and the skin was rinsed under deionised 
water then mounted into vertical Franz diffusion cells (PermeGear, Inc., Bethlehem, PA, 
USA) with the external SC surface facing the donor chamber. The area available for 
2
transport was approximately 3 cm . The receptor chambers (volume ~ 6 ml) were filled 
with phosphate-buffered saline (PBS: 137 mM NaCl, 10 mM phosphate, 2.7 mM KCl) at 
pH 7.4. To verify skin integrity and allow thermal equilibration, the cells were inverted and 
observed for leaks. After 30 minutes the cells were returned to the upright position and 
connected to a water bath set at 32 ºC and a syringe pump (“Genie” Kent programmable 
syringe pump, Kent Scientific Corporation, Litchfield, CT, USA). Thermal equilibration 
took place whilst the formulation was being applied and initiation the experiment began 
after application of the formulation was complete and the donor compartment covered with 
TM
Parafilm . The receptor solution was stirred magnetically. 1 ml samples were collected 
and replaced with fresh buffer at 60 minute intervals over six hours. Following passive 
diffusion, the skin was removed from the cell and the cream was gently wiped off using a 
TM
dry paper towel and three isopropyl alcohol wipes and stored between Parafilm sheets 
until the next procedure. For tape stripping, the skin was pinned to a polystyrene board and 
a circular template was attached to demarcate the boundary. Baseline transepidermal water 
loss (TEWL) was measured (Biox Aquaflux AF102, Biox Systems Ltd., London, UK) and 
the skin was subjected to multidirectional sequential tape stripping with adhesive tapes 
(Scotch No. 845 book tape. 3M, St. Paul, MN, USA) that had been previously weighed 
using a 0.1 μg precision balance (Sartorius AG SE-2F semi-microbalance, Sartorius AG, 
Göttingen, Germany) and electrically discharged (anti-static device, Eltex, Germany). 
TEWL measurements were made after every other tape strip and monitored as an indicator 
-2 -1
of total SC removal (when TEWL ~ 100 gm h ). For the controls, deionised water was 
used in place of the cream. 
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Sample Analysis 
After tape-stripping, the tapes were re-weighed to allow the mass and thickness of SC 
removed to be calculated. The zinc was extracted from the tapes by shaking overnight 
®
(IKA HS 260 Basic shaker, IKA Werke GmbH & Co., KG, Germany) in 10% acetic acid. 
Prior to analysis, all samples were appropriately diluted with 10% acetic acid to facilitate 
analysis by using an inductively coupled plasma sequential atomic emission spectrometer 
(ICP- AES) (JY Horiba Ultima, Japan) fitted with a Burgener T2100 Nebulizer and JY 
Horiba AS421 autosampler set at a wavelength of 213.9 nm. Calibration standards were 
prepared from dilution of 1000 ppm Primar F Zinc Standard from Fisher Scientific Ltd. 
(Fig. 1) 
2
Fig. 1 Calibration curve for zinc standards using ICP-AES (n = 6 per standard). (r = 0.9997) 
To enable an estimation of mass balance, the original donor solutions of 5% w/v and 50% 
w/v aqueous ZnCl2 (not used in passive diffusion experiments) were also diluted and 
®
analysed. All solutions were prepared with deionised water, 18.2 MΩ-cm (NANOpure
TM
DIamond Life Science (UV/UF) Ultrapure Water System, Barnstead International 
Dubuque, Iowa, USA). 
Data Analysis and Statistics 
SC thicknesses were calculated from the TEWL measurements recorded during tape 
stripping using a modified form of Fick‟s 1st Law of diffusion as described previously. 
Normality tests, non-linear regression and statistical analyses were performed using 
®
GraphPad Prism 4.00 software (Graph Pad Software Inc., San Diego, CA, USA). 
Statistical significance between multiple data sets was determined via one-way ANOVA. 
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The confidence interval was adjusted to 95% and the significance level was set at P < 0.05. 
Outliers, determined by Grubb‟s test (http://www.graphpad.com/quickcalcs/index.cfm), 
were removed from data analysis. 
Results 
The zinc profiles in the stratum corneum of skin treated with 1% w/w zinc lactate cream, 
2% w/v zinc lactate and the control (deionised water) are shown in Fig. 2. The amount of 
zinc extracted from skin treated with the 1% w/w zinc lactate cream (blue) is higher than 
that from the 2% w/v zinc lactate formulation (red). The control (empty circles) showed 
the lowest levels of zinc extracted. A semi-logarithmic graph of the same data (Fig. 2b) 
expands the distribution of the data points but does not show clear differentiation of the 
treatment groups. 
a) b) 
Fig. 2 The uptake of zinc into the stratum corneum expressed as the amount of zinc per sample as a function 
of normalised stratum corneum depth. Higher levels of zinc were extracted from 1% w/w cream compared to 
the 2% w/v zinc lactate formulation. Endogenous zinc from the control is seen in the lower regions of the 
graph (open circles). 
The quantities of zinc per unit mass of stratum corneum as a function of stratum corneum 
depth are shown in Fig. 3. The treatments fall into two groups, which are not clearly 
separated from each other. 
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a) b) 
Fig. 3 Penetration profiles of zinc delivered per unit mass of stratum corneum expressed as a function of 
stratum corneum depth. Separation of the 1% w/w zinc lactate cream data is clearer in the semi-logarithmic 
plot (b). 
The cumulative amounts of zinc in the stratum corneum as a function of stratum corneum 
depth are shown in Fig. 4. The graphs show that the levels of zinc delivered to the stratum 
corneum from the two formulations are higher than the control indicating that zinc did 
penetrate into the skin from the two formulations. 
a) b) 
Fig. 4 Cumulative amounts of zinc in the stratum corneum as a function of stratum corneum depth. 
The total quantities of zinc recovered in the control, 1% w/w zinc lactate cream and 2% 
w/v zinc lactate treated skin are shown in Fig. 5 and were 0.83 ± 0.59 μg, 4.99 ± 1.59 μg 
and 2.58 ± 1.93 μg, respectively. Zinc delivered from the 1% w/w zinc lactate cream was 
approximately twice that from the 2% w/v formulation. A one-way ANOVA carried out on 
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Fig. 5 The cumulative amounts of zinc extracted from untreated skin (control) and skin treated with 1% w/w 
zinc lactate cream and 2% w/v zinc lactate formulation; the mean (± SD) values are indicated for n = 9, 10 
and 6, respectively. 
Tukey‟s multiple comparison test detected significant differences between control and 1% 
w/w zinc lactate cream (P < 0.001), and also between 1% w/w zinc lactate cream and 2% 
w/v zinc lactate formulation (P < 0.01). 
Cumulative amounts of zinc detected in the receptor solutions as a function of time are 
shown in Fig. 6. Overlapping of the control and treated skin data can be observed (Fig. 6a). 
Total penetration of zinc for the control and 1% w/w zinc lactate cream and 2% w/v zinc 
lactate formulation (mean ± SD, where n = 9, 10 and 6) were 1.74 ± 0.6 μg, 1.52 ± 0.5 μg 
and 1.39 ± 0.3 μg, respectively. No significant differences were detected between 
treatment groups using one-way ANOVA (P = 0.43). 
83



















































1.74 g   0.6
1.52 g ± 0.5































Percutaneous Penetration of Zinc from Novel Formulations 
a) b) 
Fig. 6 (a) Hourly samples of receptor compartments showed low levels of zinc. (b) No statistical difference 
was observed in the zinc content of receptor solutions between treatment groups, P = 0.43. 
Discussion 
The results of many studies have shown that zinc oxide has very limited penetration into 
the skin. (36-43) In a recent study, ultrafine zinc oxide (Z-COTE) was applied intact 
human skin in vitro and imaged using x-ray spectroscopy and scanning transmission ion 
microscopy. The results revealed that the penetration of zinc was limited to the outer 
surface of the skin. Even when the stratum corneum was partially or entirely removed, no 
penetration of zinc was observed in the deeper skin layers.(44) 
In this chapter, the performance of a 2% w/v zinc lactate formulation (the prototype of the 
resulting cream formulation) and a 1% w/w zinc lactate cream was assessed. The results of 
this investigation show that the uptake of zinc from a 1% w/w zinc lactate cream (prepared 
by York Pharma Plc.) into the stratum corneum of porcine abdominal skin was 
approximately twice that of the 2% w/v zinc lactate formulation, and five-times greater 
than the endogenous level of the element (4.99 ± 1.59 μg, 2.58 ± 1.93 μg and 0.83 ± 0.59 
μg, respectively). The amount of zinc penetrated (minus levels detected from endogenous 
sources) into the stratum corneum as a percentage of the applied dose was approximately 
0.07% and 0.004% from the 1% w/w and 2% w/v zinc formulations, respectively. The 
difference in zinc delivery between the prototype and the cream formulation could be due 




only four components; lactic acid, zinc lactate, glycerol and deionised. However, the cream 
may have contained penetration enhancers or surfactants that may have facilitated delivery 
of zinc into the skin. Further, another explanation for the difference in performance could 
be due to the variation in zinc lactate particle size between formulations. Since this 
information is not available, it is therefore, not possible to draw firm conclusions based on 
this hypothesis. Additionally, since the composition of the cream formulation is unknown, 
these theories can only be speculative. 
Amounts of zinc extracted from skin treated with zinc chloride (Chapter 3), as a percentage 
of the applied dose from both 5% and 50% ZnCl2 was 0.04% (where zinc uptake was 57 ± 
21 μg and 489 ± 117 μg, respectively). The amount of zinc uptake into the skin from the 
1% w/w zinc lactate cream was more than twice that value. The amounts of zinc delivered 
into the skin from these commercial formulations; zinc and castor oil (7.5% w/w ZnO), 
® ®
Sudocrem (15.25% w/w ZnO) and Morhulin (38% w/w ZnO), were 8.47 ± 5.67 μg, 
14.15 ± 6.92 μg and 57.9 ± 35.4 μg, respectively. Expressed as a percentage of the applied 
®
dose: 0.02%, 0.02% and 0.03%. So, although Morhulin delivered the highest level of zinc 
to the skin, when the amounts were normalised against the dose of zinc applied, it is clear 
that the 1% w/w zinc lactate cream was more effective at delivering zinc to the skin. 
In conclusion, the novel 1% w/w zinc cream performed most efficiently and has potential, 
with further optimisation, to achieve even better delivery. Even though the percent dose 
delivered was low, all the zinc would have been available in molecular form (the zinc 
lactate being fully dissolved in the formulation), unlike that taken up from the older 
preparations. In addition, it would be logical to expect a higher zinc uptake when applied 
to uninvolved or involved skin of eczema patients. 
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Chapter Six: Delivery of zinc to the skin - Imaging by 
Scanning Electron Microscope 
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Summary 
Background - Zinc is widely used in commercial formulations for the treatment of a variety 
of skin conditions. It is also one of the main ingredients in many sunscreen preparations. In 
previous chapters of this thesis, percutaneous penetration of zinc from a range of vehicles 
has been investigated. However, the effects of formulation and surface cleaning the 
topographical or distribution of zinc on and in the skin has not yet been fully characterised. 
Objectives - To investigate the effects of different zinc formulations and two surface 
cleaning procedures on the topographical distribution of zinc on the stratum corneum after 
passive diffusion. 
Methods - Porcine abdominal skin was treated with deionised water (control) and several 
®
zinc-containing formulations: 5% and 50% w/v aqueous zinc chloride, Morhulin (38% 
w/v ZnO), and 2% w/v zinc lactate in either 20:80 or 80:20 v/v glycerol/water. Post 
treatment, the skin surface was cleaned either by dry wiping, rinsing with deionised water, 
or swabbing with an isopropyl alcohol wipe. All treated skin samples were then imaged 
using scanning electron microscopy and the presence of zinc was detected using energy 
dispersive X-ray (EDX) microanalysis. The spatial distribution of zinc was studied by 
electron mapping of the skin surface. 
Results - Topographical features observed included areas of skin with either „rough‟ or 
„smooth‟ appearance, so-called furrows and hairs/hair follicles. Rinsing skin with treated 
with zinc chloride solutions removed substantial amounts of the element from rougher skin 
areas, furrows and hairs (but not from smoother regions of skin). The uptake of larger 
amounts of zinc from 50% w/v ZnCl2 than from a 5% w/v solution was clearly shown. 
®
Skin treated with Morhulin showed a white film-like deposit on the skin surface. The zinc 
lactate formulations delivered less zinc into the SC than the ZnCl2 solutions. 
Conclusions - EDX spectra and element maps provide useful complimentary information 
on the uptake and disposition of zinc following its delivery to the skin in different 
formulations. The presence of zinc was detected on the surface of skin treated with 5 and 
50% w/v ZnCl2. 50% w/v ZnCl2 solution delivered more zinc to the skin as shown by EDX 
spectra and element maps. Rinsing the skin with deionised water proved to remove zinc 
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more effectively than wiping with a dry paper towel. Of all the formulations tested, 50% 
w/v ZnCl2 delivered the highest amount of zinc to the skin. 
Keywords: Scanning electron microscopy (SEM), energy dispersive X-ray microanalysis 





It is evident from work previously carried out (and detailed in earlier chapters) that the 
delivery of zinc to the skin from a variety of formulations penetrates into, and remains 
largely in the upper layers of the stratum corneum. Since the removal of successive layers 
of skin by tape stripping only provides the overall amount of zinc delivered into the SC 
analysed, it is pertinent to investigate whether any localisation of zinc to specific skin 
areas, or structures occurs. A useful technique for this purpose is electron microscopy yet, 
while the penetration of zinc oxide (and titanium dioxide) has been the subject of 
numerous studies (1-6), the application of microscopy to visualise the fate of zinc in the 
skin has received little attention (7-13). In contrast, most previous studies have primarily 
focused on the health and safety aspects of applying sunscreens to the skin and have been 
concerned with whether nanoparticles are able to pass through the epidermis and into the 
systemic circulation where they may elicit local or systemic toxicity. 
In this experimental chapter, scanning electron microscopy and energy dispersive X-ray 
(EDX) microanalysis have been used to monitor the disposition of zinc on and into the 
stratum corneum following topical application of various zinc-containing formulations. 
The imaging undertaken has also allowed any detrimental effects on the skin of the 
formulations used (e.g., concentrated solutions of zinc chloride) to be assessed. 
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Materials & Method 
Materials:

Chemicals: Zinc chloride, 99.995 +% purity was purchased from Sigma-Aldrich, Inc. (St. 

®
Louis, MO, USA). Morhulin Ointment was from Actavis UK Ltd (Devon, England, UK). 
Zinc oxide (puriss grade), glycerol (meets BP, EP, JP, USP testing specifications), DL-
lactic acid (meets analytical specifications of Ph.Eur, BP and USP) were obtained from 
Sigma-Aldrich (Steinheim, Germany) Sodium chloride, disodium hydrogen phosphate, 
potassium phosphate, and potassium chloride were all purchased from Acros Organics 
(Belgium). Glacial acetic acid (HLPC grade) was from Fisher Scientific. 
Skin preparation 
Porcine abdominal skin obtained from a local piggery (B & J Pigs Ltd., Somerset, UK) was 
cleaned under cold running water and dermatomed to a thickness of approximately 750 μm 
TM
(Zimmer Electric Dermatome, Dover, OH, USA). The pieces of skin were then wrapped 
TM
in Parafilm , placed into a sealed bag and stored in a freezer at -20°C until required. 
Zinc chloride solutions: Aqueous solutions of zinc chloride, 5% w/v and 50% w/v, were 
freshly prepared for each experiment. 
Zinc lactate preparation: Zinc oxide (2% w/v) and lactic acid (0.2% w/v) were dissolved in 
20:80% v/v glycerol/water (gly/H2O) to create a 2% w/v zinc lactate formulation at pH 4.5. 
A 80:20% v/v gly/H2O zinc lactate formulation was also prepared. 
1
Buffer: Phosphate buffered saline, pH 7.4 was prepared using a standard formula.
® TMAll solutions were prepared with deionised water, 18.2 MΩ-cm (NANOpure DIamond
Life Science (UV/UF) Ultrapure Water System, Barnstead International, Dubuque, Iowa, 
USA). 
Zinc delivery into SC                                                    
The skin was thawed and visually inspected for defects and punctures. Excess hair was 
carefully trimmed, the skin was rinsed under deionised water and then cut into three. These 




flow-through diffusion cells (PermeGear, Inc., Bethlehem, PA, USA) with the external SC 
surface facing the donor compartment. The receptor compartments were filled with PBS at 
pH 7.4 (volume ~ 6 ml) and the cells were temporarily inverted to verify skin integrity. 
After approximately 20 minutes the cells were returned to an upright position and the 
donor solutions (3 ml): (i) deionised water, (ii) 5% ZnCl2, and (iii) 50% ZnCl2 were 
TM 
pipetted into donor chambers. Each donor was covered with Parafilm and the cells were 
placed onto a magnetic stirrer and connected to (a) a water bath set at 32 ºC and (b) a 
“Genie” Kent programmable syringe pump (Kent Scientific Corporation, Litchfield, CT, 
USA). Receptor samples of 1 ml were collected every hour. After six hours of passive 
diffusion, the donor solutions were discarded and the skin samples dismounted from each 
cell. Where applicable, the pieces of skin were then cut into two portions one of which was 
dried using a dry paper towel, while the other was rinsed under de-ionised water. In 
preparation for inspection under the scanning electron microscope (SEM), the pieces of 
skin were flash frozen in liquid nitrogen then freeze dried (BOC Edwards Freeze Dryer, 
NY, USA) overnight. The samples were coated (BOC Edwards Sputter Coater S150B) 
with a fine layer of gold before analysis under the scanning electron microscope (SEM). 
®
The experiments were repeated using Morhulin , 2% zinc lactate (20:80% gly/H2O) and 
2% zinc lactate (80:20% gly/H2O) as donors formulations all of which were applied in 
excess. 
Scanning electron microscopy (SEM) 
SEM images were obtained using a JEOL 6480LV SEM (Japan). The microscope was set 
at a magnification of x350, an accelerating voltage of 20kV, a spot size of 25 and a 
working distance 10mm. Other parameters were adjusted to optimum values. 
To collect the X-ray microanalysis data, the microscope was set to an accelerating voltage 
of 20kV, a spot size of 50 and a working distance 10mm. All other parameters were 
adjusted to optimum values to give a minimum count rate of 1.3 - 1.5 kcps, and a dead 
time of < 10%. Spectra were collected for 100 seconds and maps for > 80 frames. The 
analysis programme used was INCA, produced by Oxford Instruments (UK). 
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Results - Part 1 
Control - skin treated with deionised water 
SEM images of the hair (and hair shaft), skin furrow, smooth and rough areas of skin 
treated with deionised water are in Fig. 1a-d. 
d) Rough area c) Smooth area 
b) Skin furrow a) Hair 
Fig. 1 SEM images of; a) hair, b) skin furrow, and c) smooth and, d) rough areas of untreated skin. The 
arrow points to an example of an unidentified organic structure present on the skin surface. 
Energy dispersive X-ray (EDX) microanalysis revealed elemental profiles on the skin 








a) Control hair b) Control skin furrow 
c) Control smooth area d) Control rough area 
Fig 2. Energy dispersive X-ray microanalysis of a) hair, b) skin furrow, and c) smooth, and d) 
rough areas of control (untreated) skin. No trace of zinc was detected anywhere. 
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Results - Part 2 
Disposition of zinc following ZnCl2 application and surface cleaning

The delivery of zinc to the skin from 5% and 50% w/v ZnCl2 solutions was investigated. 

The use of 2 cleaning procedures was also studied: rinsing with deionised water or wiping 

with a dry paper towel.

Hair and skin furrows 
Zinc deposits were observed on hairs present on skin which had been wiped with a dry 
paper towel after treatment with 5 and 50 % w/v ZnCl2 (Fig. 3a-b). Treated skin rinsed 
with deionised water did not show zinc coating on the hairs and surrounding areas which 
appeared clean and smooth (Fig. 3c-d). With regard to furrows, no visible change to the 
topography of the skin was apparent between different zinc treatments after removing the 
excess with a paper towel (Fig. 3e-f). No significant differences were observed between 




a) Hair: 5% w/v ZnCl2, Wiped b) Hair: 50% w/v ZnCl2, Wiped 
c) Hair: 5% w/v ZnCl2, Rinsed d) Hair: 50% w/v ZnCl2, Rinsed 
e) Furrow: 5% w/v ZnCl2, Wiped f) Furrow: 50% w/v ZnCl2, Wiped 
g) Furrow: 5% w/v ZnCl2, Rinsed h) Furrow: 50% w/v ZnCl2, Rinsed 
Fig. 3 SEM Images of hair and skin furrows. Left and right panels were treated with 5 and 
50 % w/v ZnCl2, respectively. Samples, a), b), e), and f), were wiped dry directly after treatment, 
while samples c), d), g) and h) were rinsed with deionised water before drying. 
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Energy dispersive X-ray (EDX) microanalysis spectra showed that levels of zinc delivered 
to the skin correlated with the concentration applied; i.e., more zinc was 
deposited/delivered to the skin from the more concentrated solution (Fig.4). Skin samples 
wiped with a paper towel directly after treatment (Fig. 4a, b, e, f) showed higher levels of 
zinc (and chlorine) than those rinsed with deionised water (Fig. 4c, d, g, h). 
c) Hair: 5% w/v ZnCl2 
Rinsed 
d) Hair: 50% w/v ZnCl2 
Rinsed 
b) Hair: 50% w/v ZnCl2 
Wiped 





g) Skin furrow: 5% w/v ZnCl2 
Rinsed 
h) Skin furrow: 50% w/v ZnCl2 
Rinsed 
f) Skin furrow: 
50% w/v ZnCl2, Wiped 
e) Skin furrow: 5% w/v ZnCl2 
Wiped 
Fig. 4 Energy dispersive X-ray (EDX) spectra of the hair and skin furrows of skin treated with

5% and 50% w/v ZnCl2 and dry wiped, or rinsed with deionised water after treatment

Element mapping showed the distribution and density of each element present on the 
surface of the skin (Fig. 5). Higher levels of zinc were observed after application of 50% 
w/v ZnCl2 than those following treatment with 5% w/v ZnCl2. In general, rinsing the skin 
with deionised water reduced the amounts of zinc present on the skin. The element maps 
indicate that zinc had equal affinity for hair and skin. Chlorine delivered from the ZnCl2 
was also observed in quantities correlated with the concentrations applied. 
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a) Hair: 5% w/v ZnCl2, Wiped 




d) Hair: 50% w/v ZnCl2, Rinsed 
c) Hair: 5% w/v ZnCl2, Rinsed 
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e) Skin furrows: 5% w/v ZnCl2, Wiped 





g) Skin furrow: 5% w/v ZnCl2, Rinsed 
h) Skin furrow: 50% w/v ZnCl2, Rinsed 
Fig. 5 Element maps showing the distribution of different elements on the skin surface 
following treatment with 5 % and 50% w/v ZnCl2 and then cleaned either with 
absorbent tissue, or rinsed under deionised water. Samples a-d show areas of the skin 
with hair, panels e-h show furrows of the skin. 
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Smooth and rough skin areas

Fig. 6 shows images of smooth and rough areas of skin after treatment with 5 and 50% 

ZnCl2 and subjected to the different cleaning methods described previously. No obvious

visual difference was observed between skin samples after treatment with 5% and 50% 





 Chapter Six 
a) Smooth: 5% w/v ZnCl2, Wiped b) Smooth: 50% w/v ZnCl2, Wiped 
c) Smooth: 5% w/v ZnCl2, Rinsed d) Smooth: 50% w/v ZnCl2, Rinsed 
e) Rough: 5% w/v ZnCl2, Wiped f) Rough: 50% w/v ZnCl2, Wiped 
g) Rough: 5% w/v ZnCl2, Rinsed h)  Rough: 50% w/v ZnCl2, Rinsed 
Fig. 6 SEM Images of smooth and rough skin areas. Left and right panels were treated with 
5% and 50% w/v ZnCl2, respectively. Samples a), b), e), and f), were wiped dry directly after 
treatment, and samples c), d), g) and h) were rinsed under deionised water before drying. 
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Spectra of smooth and rough skin areas showed that levels of zinc detected was dependent 
on the concentration applied and the type of cleaning method utilised after passive 
diffusion; i.e., the more concentrated ZnCl2 solution delivered more zinc to the skin which 
was more efficiently removed by washing with deionised water (Fig.7). While the zinc 
cannot be quantified in the images, qualitative comparisons are possible. The amounts of 
zinc detected on smooth and rough surfaces appeared were similar for the same donor 
concentrations (Figs. 7a, e, b, f). Rinsing the skin with deionised water clearly removed 
zinc from the skin surface (Figs. 7c, d, g, h). 
d) Smooth area: 
50% w/v ZnCl2, Rinsed 
c) Smooth area: 5% w/v ZnCl2 
Rinsed 
a) Smooth area: 5% w/v ZnCl2 
Wiped 
b) Smooth area: 




h) Rough area: 50% w/v ZnCl2 
Rinsed 
g) Rough area: 5% w/v ZnCl2 
Rinsed 
e) Rough area: 5% w/v ZnCl2 
Wiped 
f) Rough area: 
50% w/v ZnCl2, Wiped 
Fig. 7 EDX spectra of the hair and skin furrows of skin treated with 5 and 50% w/v ZnCl2 and 

wiped, or rinsed with deionised water after treatment

The presence and levels of zinc on the skin were confirmed by element maps (Fig. 8). 
Higher levels of zinc were observed on skin treated with 50% w/v ZnCl2 compared to 5% 




Delivery of zinc to the skin - Imaging by Scanning Electron Microscope 
a) Smooth skin: 5% w/v ZnCl2, Wiped 





c) Smooth skin: 5% w/v ZnCl2, Rinsed 
d) Smooth skin: 50% w/v ZnCl2, Rinsed 
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e) Rough skin: 5% w/v ZnCl2, Wiped 




h) Rough skin: 50% w/v ZnCl2, Rinsed 
g) Rough skin: 
5% w/v ZnCl2, Rinsed 
Fig. 8 Element maps showing the distribution of different elements on smooth and rough skin

surfaces treated with 5 % and 50% w/v ZnCl2 and then cleaned either with absorbent tissue, 







Delivery of zinc to the skin - Imaging by Scanning Electron Microscope 
Results - Part 3 
Comparison of zinc delivery from various formulations

Delivery of zinc to the skin from 2% Zn lactate (20:80 and 80:20 gly/H2O), 5% and 50% 

®
ZnCl2 and Morhulin (38% ZnO) was investigated. Excess formulation was removed 
®




Fig. 9a-f show hairs on the skin surface after treatment with the different zinc preparations. 

®
With the exception of skin treated with Morhulin (Fig. 9e) (which appeared to leave a thin 
white coating on the hair and surrounding areas of skin), there was no obvious visual 
difference between the formulations; no deposits, degradation of the skin or hair, or 
discolouration, were observed. 
EDX spectra of the hairs and surrounding areas showed no zinc detected on the control 
(H2O), or 2% w/v Zn lactate treated skin (Fig. 10 a-c). The absence of zinc was confirmed 
in corresponding element maps of the skin surfaces (Fig. 11a-b). A small zinc peak was 
observed in Fig 10d, which corresponded to skin treated with 5% w/v ZnCl2. Larger peaks 
®
were present in spectra from skin treated with Morhulin (38% w/w ZnO) and 50% w/v 
ZnCl2 (Fig. 10e-f). Where concentrations were sufficient, small secondary zinc peaks were 
visible at 8.6 keV (Fig. 10d-f). Background levels of chlorine (thought to be naturally 
occurring) was observed in Figs. 10a- c, e. Larger chlorine peaks (approximately twice the 
size of the zinc peaks) were observed in Fig. 10d, f with ZnCl2. The corresponding element 
maps also detected higher levels of chlorine (Fig. 11c, e). 
Calcium and traces of aluminium of unknown origin were detected in the spectrum of the 
control (Fig, 10a). A small sodium peak was seen in the spectrum of 2% Zn lactate (80:20, 
gly/H2O) treated skin (Fig. 10c) which was not present in the element map possibly due to 
the concentration falling below the limit of detection (Fig. 11b). Sulphur was also present 
in each EDX spectrum (Fig.9 a-h) and was concentrated in the hairs (Fig. 11). 
The EDX spectra concur with the element maps in that no zinc was detected in the control 





ZnCl2 and Morhulin treated skin and that the levels detected increased with the increasing zinc 
concentration applied (Fig. 11c-e). 
a) Control (Deionised H2O) b) 2% Zn lactate (20:80, gly/H2O) 
c) 2% Zn lactate (80:20, gly/H2O) d) 5% w/v ZnCl2 
®
e) Morhulin (38% ZnO) f) 50% w/v ZnCl2 
Fig. 9 SEM images of hairs on the surface of the skin: panels (a) through (f) represent treatment with 
deionised water (control), 2% w/v zinc lactate (20:80, gly/H2O), 2% w/v zinc lactate (80:20, gly/H2O), 5% 
w/v ZnCl2, Morhulin
®
, and 50% w/v ZnCl2, respectively. 
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f) 50% w/v ZnCl2e) Morhulin
® 
(38% w/w ZnO) 
d) 5% w/v ZnCl2c) 2% w/v Zn lactate 
(80:20, gly/H2O) 
a) Control (deionised H2O) b) 2% w/v Zn lactate 
(20:80, gly/H2O) 
Fig.10 EDX spectra of hairs and surrounding skin areas following application of 
a) deionised water (control), b) 2% w/v zinc lactate (20:80, gly/H2O), c) 2% w/v 
®




b) 2% w/v Zn Lactate (80:20, gly/H2O) 




Delivery of zinc to the skin - Imaging by Scanning Electron Microscope 
d) Morhulin
® 
(38% w/w ZnO) 




e) 50% w/v ZnCl2 
Fig. 11 Element maps showing the distribution of different elements on and around hairs 
following application of a) deionised water (control), b) 2% w/v zinc lactate 
(20:80, gly/H2O), c) 2% w/v zinc lactate (80:20, gly/H2O), d) 5% w/v ZnCl2, e) Morhulin
®
, 
and f) 50% w/v ZnCl2. 
Skin furrows 
Images of skin furrows post-treatment are shown in Fig. 12. No visible signs of deposits or 
changes in structure were observed on skin treated with deionised water (control), 2% w/v 
®
Zn lactate and 5% w/v ZnCl2 (Fig. 12a-d). On closer inspection, Morhulin treated skin 
appeared to be coated with a thin white film of deposit (Fig. 12e). Skin treated with 50% 




Delivery of zinc to the skin - Imaging by Scanning Electron Microscope 
Fig. 12 SEM images of furrows on the skin surface. Panels (a) through (f) represents treatment with 
e)  Morhulin
® 
(38% w/w ZnO) f) 50% w/v ZnCl2 
a) Control (deionised H2O) b) 2% w/v Zn lactate (20:80, gly/H2O) 
c)  2% w/v Zn lactate (80:20, gly/H2O) d) 5% w/v ZnCl2 
deionised water (control), 2% w/v zinc lactate (20:80, gly/H2O), 2% w/v zinc lactate (80:20, gly/H2O), 5% 
w/v ZnCl2, Morhulin
®
, and 50% w/v ZnCl2, respectively. 
EDX spectra of skin furrows are shown in Fig. 13. No zinc was detected in the control or 2 
% w/v zinc lactate (80:20, gly/H2O) treated skin (Fig. 13a, c). Small peaks were visible for 
2% w/v zinc lactate (20:80, gly/H2O) and 5% w/v ZnCl2 (Fig. 13b, d) treated skin. The 
®
main zinc peak seen in Fig. 13e is smaller than that seen in Fig. 10e for Morhulin (hair) 




50% w/v ZnCl2 is similar in size to that seen previously in Fig. 10f and is the largest out of 
all spectra indicating the highest amount of zinc present on the skin. 
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e) Morhulin 
® 
(38% w/w ZnO) f) 50% w/v ZnCl2 
d) 5% w/v ZnCl2c) 2% w/v Zn lactate 
(80:20% gly/H2O) 
a) Control (deionised H2O) b) 2% w/v Zn lactate 
(20:80% gly/H2O) 
Fig. 13 EDX spectra of furrows following application of a) deionised water 
(control), b) 2% w/v zinc lactate (20:80, gly/H2O), c) 2% w/v zinc lactate 
®




The EDX spectrum of 2% Zn lactate (20:80, gly/H2O) treated skin showed a small peak for 
zinc (Fig. 13b), which was not present in the element map (Fig. 14a). In agreement with 
the EDX results, the element map of Zn lactate (80:20, gly/H2O) treated skin did not show 
®
the presence of zinc (Fig. 14b). Zinc was detected in Morhulin (38% ZnO), 5% and 50% 
w/v ZnCl2 treated skin (Fig. 14c-e). The overall density of zinc observed in the maps of 5% 
®
w/v ZnCl2 and Morhulin (38% ZnO) treated skin appeared similar (Fig. 14c, 14d); the 
only difference was the concentration of zinc that in the furrow of the latter (Fig. d). 
The zinc level detected on the surface of 50% w/v ZnCl2 treated skin corresponds to the 
®
high concentration applied (Fig. 14 e). With the exception of Morhulin , uniform 
distribution of zinc was observed in the respective element maps of the samples (Fig, 14 a-
c, e). 
a) 2% w/v Zn lactate (20:80, gly/H2O) 
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c) 5% w/v ZnCl2 




e) 50% w/v ZnCl2 
d) Morhulin
® 
(50% w/w ZnO) 
Fig. 14 Element maps showing the distribution of different elements in the proximity of skin 
furrows following application of a) 2% w/v zinc lactate (20:80, gly:H2O), b) 2% w/v zinc 
®





Delivery of zinc to the skin - Imaging by Scanning Electron Microscope 
Smooth areas of skin 
No difference was observed in smooth areas of skin after treatment with various zinc 
preparations (Fig. 15). 
f) 50% w/v ZnCl2e)  Morhulin
® 
(38% w/w ZnO) 
d) 5% w/v ZnCl2c)  2% Zn lactate (80:20, 
a) Control (Deionised H2O) b) 2% Zn lactate (20:80, gly/H2O) 
Fig. 15 SEM images of smooth areas of skin following application of a) deionised water (control), b) 2% w/v 
®
zinc lactate (20:80, gly:H2O), c) 2% w/v zinc lactate (80:20, gly:H2O), d) 5% w/v ZnCl2, e) Morhulin (38% 




a) Control (Deionised H2O) b) 2% w/v Zn lactate 
(20:80% gly/H2O) 




(38% w/w ZnO) 
f) 50% w/v ZnCl2 
Fig. 16 EDX spectra of smooth areas of skin following application of a) deionised 
water (control), b) 2% w/v zinc lactate (20:80, gly:H2O), c) 2% w/v zinc lactate 
(80:20, gly:H2O), d) 5% w/v ZnCl2, e) Morhulin (38% ZnO)
®
, and f) 50% w/v ZnCl2. 
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Fig. 16 shows the EDX spectra of skin samples treated with different concentrations of 
zinc in a variety of formulations. No zinc was detected in the control (deionised water) or 
in 2% w/v Zn lactate treated skin (Fig. 16a-c). Small zinc peaks were observed in 5% w/v 
®
ZnCl2 and Morhulin treated skin (Fig. 16d, e). Overlap of the zinc and sodium peaks in 
Fig. 16e makes comparison difficult with zinc peaks from other formulations. The zinc 
peak corresponding to 50% w/v ZnCl2 treated skin was the largest of all (Fig. 16f). 
Fig. 17 shows element maps of smooth skin. Zn lactate treated skin did not show any zinc 
on the surface of the skin (Fig. 17a-b). Amounts and distribution of zinc on skin treated 
®
with Morhulin and 5% ZnCl2 were similar (Fig. 17c-d). 50% w/v ZnCl2 treated skin 
showed the highest levels of zinc (Fig. 17e). All elements detected in EDX spectra were 
observed in the element maps (Fig. 16-17). Zinc levels measured in the EDX spectra (Fig. 
16 d-f) appeared to correlate with those visible in the element maps (Fig. 17 c-e). 




b) 2% w/v Zn lactate 
(80:20, gly/H2O) 
c) 5% w/v ZnCl2 
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e) 50% w/v ZnCl2 
d) Morhulin
® 
(38% w/w ZnO) 
Fig. 17 Element maps showing the distribution of different elements in the proximity of 
smooth skin following application of a) 2% w/v zinc lactate (20:80, gly:H2O), b) 2% w/v 
zinc lactate (80:20, gly:H2O), c) 5% w/v ZnCl2, d) Morhulin
®




Rough areas of skin 
SEM images of rough skin areas shown in Fig. 18. No differences in appearance after 
treatment with the various zinc preparations were observed. 
a) Control (Deionised H2O) b) 2% w/v Zn lactate (20:80, gly/H2O) 
c) 2% w/v Zn lactate (20:80, gly/H2O) d) 5% w/v ZnCl2 
e) Morhulin
® 
(38% w/w ZnO) f) 50% w/v ZnCl2 
Fig. 18 SEM images of smooth areas of skin following application of a) deionised water (control), b) 2% 
w/v zinc lactate (20:80, gly/H2O), c) 2% w/v zinc lactate (80:20, gly/H2O), d) 5% w/v ZnCl2, e) 
Morhulin
®
(38% w/w ZnO), and f) 50% w/v ZnCl2. 
133

Delivery of zinc to the skin - Imaging by Scanning Electron Microscope 
EDX spectra revealed no zinc on rough skin surfaces of the control and of 2% w/v Zn 
®
lactate treated skin (Fig. 19a-c). Skin treated with Morhulin (38% w/w ZnO), and 5% and 
50% ZnCl2 clearly showed the presence of zinc detected with the level following treatment 
peak of 50% w/v ZnCl2 being the largest (Fig. 19d-f). 
Element maps of rough surfaces are in Fig. 20. No zinc was detected on zinc lactate treated 
skin (Fig. 20a, b). Similar levels of zinc were detected on skin treated with 5% w/v ZnCl2 
®
and Morhulin (Fig. 20c-d). The amount of zinc observed on skin treated with 50% w/v 




e) Morhulin® (38% w/v ZnO) f) 50% w/v ZnCl2 
a) Control (H2O) b) 2% w/v ZnLact 
(20:80% gly/H2O) 
d) 5% w/v ZnCl2c) 2% w/v ZnLact 
(80:20% gly/H2O) 
Fig. 19 EDX spectra of rough areas of skin following application of a) deionised water 
(control), b) 2% w/v zinc lactate (20:80, gly:H2O), c) 2% w/v zinc lactate 
®
(80:20, gly:H2O), d) 5% w/v ZnCl2, e) Morhulin (38% ZnO) , and f) 50% w/v ZnCl2. 
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a) 2% w/v Zinc Lactate (20:80, gly/H2O) 






(38% w/w ZnO) 
c) 5% w/v ZnCl2 
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e) 50% w/v ZnCl2 
Fig. 20 Element maps showing the distribution of different elements on rough skin 
following application of a) 2% w/v zinc lactate (20:80, gly:H2O), b) 2% w/v zinc lactate 
®
preparations containing ZnCl2, zinc lactate and zinc oxide (Morhulin ); changes to the 
(80:20, gly:H2O), c) 5% w/v ZnCl2, d) Morhulin , and e) 50% w/v ZnCl2 
Discussion 
The purpose of these experiments was to explore further the delivery of zinc from 
®
topography of the skin were also examined and the efficiency of two different cleaning 
procedures (wiping with a dry paper towel and rinsing with deionised water) on zinc 
distribution and penetration into the skin was assessed. The control experiment considered 
skin treated with deionised water alone, and evaluated the visual appearance and the 
presence of naturally occurring elements, including zinc. In these studies, skin was imaged 
by SEM post-treatment. EDX spectroscopy and elemental mapping was used to determine 
the distribution, localisation and elemental composition of each skin sample. Due to the 
heterogeneity of the skin surface, four different structural regions were analysed; hair, 
furrow, smooth and rough skin. Formulation trapped in these sites makes differentiation 





The SEM images (Fig. 1) revealed small, randomly distributed spherical structures on the 
skin that were entirely organic in composition (results not shown). EDX spectra 
characterised the elemental composition of the skin surface (Fig.2), and showed the 
presence of chlorine, carbon, calcium, oxygen, sodium, sulphur (mainly from hair), some 
aluminium (likely to be contamination) and potassium. Since all samples were coated in 
gold before analysis, this element was also detected in all EDX and element maps. No 
naturally-occurring, background zinc was detected in control samples even though 
previous work (Chapter 3) demonstrated that zinc was present in the stratum corneum at a 
2
level of approximately 1 µg/cm (± 0.6). Presumably, this level was below the limit of 
detection of EDX spectroscopy and element mapping. 
Distribution of zinc on skin: Comparison between 5% and 50 % w/v ZnCl2 and between 
different cleaning methods 
Images of the skin after treatment with 5% and 50% ZnCl2 showed residue attached to the 
hair and surrounding areas (Fig. 3a, b). The substance, which was not present on control 
samples (Fig. 1a), was assumed to be ZnCl2 since it was readily removed by rinsing the 
sample under deionised water indicating that it was water soluble (Fig. 3c-d) (as is ZnCl2). 
In element maps of hair on skin treated with 50% w/v ZnCl2, the zinc decreased after 
rinsing with water was observed (Fig. 5b, d). Rough areas on skin treated with 50% w/v 
ZnCl2 also showed deposits on the surface, which was not present on skin rinsed with 
water after treatment (Fig. 6f, h). With the exception of the aforementioned areas, SEM 
images of furrows, smooth areas treated with 5% and 50% w/v ZnCl2, and also rough areas 
on skin treated with 5% w/v ZnCl2, showed no differences in topography between zinc 
treatments or cleaning procedures was observed (Figs. 3c-h, 6a-e, g). 
The presence of zinc on the surface of the skin is shown in the EDX spectra (Fig.4). While 
it was not possible to quantify the amounts of zinc detected however, relative amounts 
were estimated by comparing peak heights and size. EDX spectra showed that 50% w/v 
ZnCl2 delivered higher levels of zinc to all skin areas than 5% w/v ZnCl2. These results 
were supported by corresponding element maps. EDX spectra also revealed that the levels 
of zinc on the skin were affected by cleaning methods, i.e., rinsing with deionised water 
removed much of the zinc adhered to the skin surface. However, element maps did not 
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Comparison of zinc delivery from different formulations 
Five different zinc preparations, (i) 2% w/v zinc lactate (20:80, gly:H2O), (ii) 2% w/v zinc 
®
lactate (80:20, gly:H2O), (iii) 5% w/v ZnCl2, (iv) Morhulin (38% w/w ZnO), (v) 50% w/v 
ZnCl2 were considered. Deionised water was used for the control. With the exception of 
®
Morhulin , there were no differences in terms of skin appearance between post-treatment 
®
(Fig. 9, 12, 15, 18). SEM images of Morhulin (38% w/w ZnO) treated skin showed a thin, 
opaque/white coating over all four areas analysed (Fig. 9e, 12e, 15e, 18e). This was largely 
due to the difficulty in removing the (viscous and oily) formulation from the skin even 
when isopropyl alcohol wipes were used. 
When skin was treated with 2% zinc lactate, with the exception of very low levels in skin 
furrows (Fig. 13b), EDX showed no zinc in any other areas (Fig. 10, 16, 19 a-c, and 13a, 
c). Small amounts of zinc were found in all four areas of skin treated with 5% w/v ZnCl2 
(Fig. 10, 13, 16, 19c). EDX spectra of hairs showed similar levels of zinc after application 
®
of Morhulin and 50% w/v ZnCl2. However, element maps indicated that zinc delivery 
®
from Morhulin was less than that from 50% w/v ZnCl2. Zinc levels in skin furrows, and on 
®
smooth and rough areas of Morhulin treated skin were small compared to those after 
application of 50% w/v ZnCl2. Element maps showed similar levels of zinc after treatment 
®
with either 5% w/v ZnCl2 or Morhulin ; for the latter, zinc accumulation was observed in 
skin furrows (Fig. 14d). This discovery was not surprising since the surface of the skin is 
not homogeneous and provides several places in which the formulation may become 
trapped and from which it is difficult to remove (even with isopropyl alcohol wipes). This 
finding is consistent with an earlier study of the dermatopharmacokinetics of 
betamethasone 17-valerate that also revealed sequestration of the formulation in skin 
furrows.(15) 
Background levels of chlorine (thought to be naturally occurring) were also observed in 
each EDX spectrum with ZnCl2 treated skin showing higher levels than others. Element 
maps also displayed high levels of chlorine after application of ZnCl2 with quantities in 
rough proportion to the concentration applied.  
In summary, the experiments revealed that (i) 50% w/v ZnCl2 delivered zinc more 
effectively to the skin than the 5% solution, (ii) rinsing the skin with water post-tretment 
removed a large fraction of the zinc adsorbed/penetrated into the SC, (iii) the zinc lactate 




SEM imaging, EDX microanalysis and element mapping offers useful tools with which to 
examine the surface of the skin and provide information regarding the distribution and 
relative levels of zinc delivered from different formulations. However, the use of EDX and 
element mapping are limited by sensitivity, and the acquisition of even semi-quantitative 
data requires that specific measurement criterion are met; for example, each sample must 
be completely flat and exactly the same distance from the microscope lens. This cannot be 
achieved without prior arduous and complicated sample preparation. 
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Chapter Seven: Absorption of Zinc from Sudocrem into Human 
Stratum Corneum In Vivo: Comparison of Uptake Determined 










Absorption of zinc from Sudocrem into human stratum corneum in vivo: 
comparison of uptake determined by different extraction methods 
Summary 
Background - Currently, there is a multitude of zinc containing products available on the 
market. These range from barrier products for contact dermatitis/nappy rash, through 
medicated bandages for eczema and psoriasis, to sunscreens to reflect harmful UV-rays. 
However, the percutaneous penetration of zinc oxide from these is limited (and, in the case 
of sunscreens, undesirable) as their main function is to provide a mechanical barrier to 
protect the skin from assault due to irritants. The development of a novel topically applied 
zinc-containing formulation for reparation of the defective skin barrier that occurs in 
eczema is in progress. Therefore, it would be pertinent to investigate the percutaneous 
®
penetration of zinc from one of the most popular products; Sudocrem
Objectives - To determine the penetration of zinc into human stratum corneum in vivo 
®
following application of Sudocrem (15.25% w/w ZnO) once (x1) to three times (x3) a 
day, and subsequently to compare tape stripping (TS), reverse iontophoresis (RI) and 
passive extraction (PE) for quantitation of zinc uptake into the skin. 
®
Methods - Sudocrem (15.25% w/w ZnO) was applied to the forearm of eight healthy 
volunteers for two weeks. Each arm was ‘divided’ into control and treated regions. One 
arm was treated with the cream once a day, the other three times. After the treatment 
period, the zinc was extracted from the skin by tape stripping (TS), reverse iontophoresis 
(RI) and passive extraction (PE). Levels of zinc were analysed by inductively coupled 
plasma - atomic emission spectroscopy (ICP-AES). 
Results - Significant statistical differences in mean cumulative concentrations of zinc 
extracted by tape stripping and passive extraction were detected between treatments 
®
(control, once and three times Sudorem application). No significant difference in mean 
cumulative concentrations of zinc extracted by cathodal and anodal RI were detected. 
Significant statistical differences was also detected between extraction methods for once 
and three-times daily applications. 
Conclusions - Tape stripping recovered the most zinc from the skin. Zinc sequestered in 
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resulting in higher concentrations measured. A statistical difference was detected in zinc 
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Zinc-containing products are widely available on the market, many of which are barrier 
preparations such sunscreens or treatments for nappy rash.(1) Their purpose is to provide a 
protective mechanical barrier that remains on the skin.(1) Penetration of zinc from such 
formulations is largely limited to the upper layers of the stratum corneum.(2-7) A detailed 
report published by the European Union’s Scientific Committee on Cosmetic Products and 
Non-Food Products (SCCPNFP) concluded that no change in zinc plasma levels occurred 
in vivo in human subjects treated with a daily application of 40% zinc oxide ointment for 
10 days; penetration of zinc was less than 1% of the applied dose and the majority of zinc 
oxide was recovered from the outermost layer of the skin, the stratum corneum.(8) 
However, with respect to formulating a novel treatment for eczema, it is desirable for zinc 
to be able to penetrate into the stratum corneum to elicit its therapeutic effects. The 
weakened skin barrier in eczema is xerotic and prone to forming cracks that facilitate the 
percutaneous influx of xenobiotics, microorganisms and allergens.(9-13) As a 
consequence, the sufferer experiences itching and soreness in the affected areas, which 
leads to scratching and the eventual formation of lesions, and in some cases, bleeding.(10, 
11, 14-17) These lesions take weeks to heal and provide additional and more direct 
pathways through the skin for irritants and allergens to cause further damage and 
inflammation, and thus delaying the healing process. The inadequate protection of the skin 
barrier is a direct result of the lack of natural moisturising factor and the increased 
desquamation of the stratum corneum. Natural moisturising factor keeps the skin hydrated, 
helps maintain flexibility and provides resistance to tearing.(18) Increased desquamation 
reduces the thickness of the skin barrier causing it to be fragile and more prone to the 
development of cracks.(18) Further, the thin barrier facilitates the ingress of irritants and 
allergens across the stratum corneum to deeper skin layers where they can cause irritation 
and discomfort. Penetration of zinc from topically applied formulations may aid barrier 
repair. In formulating a novel treatment for such purposes, it is pertinent to examine the 
performance of a commercially available zinc-containing product in terms of the 
penetration of zinc into the skin. 
This report details the absorption of zinc into the skin of human forearms in vivo from a 
®
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Determination of the most efficient method for the extraction and quantitation of zinc from 
the skin has also been investigated. 
Materials and Methods 
Materials 
®
Sudocrem (15.25% zinc oxide) was purchased from Forest Tosara, Dublin, Ireland, 
TM
Scotch No. 845 book tape was purchased from 3M (St. Paul, MN, USA), Micropore tape 
was from 3M (Nadarzyn, Poland). The tape stripping template (2 cm diameter aperture) 
was constructed from book tape. Silver wire (> 99.99% purity) and silver chloride (> 
99.999%) were purchased from Sigma-Aldrich Co. (Gillingham, UK). Glacial acetic acid 
(HLPC grade) was from Fisher Scientific. The reverse iontophoresis extraction solution 
comprised of 3 mM saline. All solutions were prepared with deionised water, 18.2 MΩ-cm 
® TM
(NANOpure DIamond Life Science (UV/UF) Ultrapure Water System, Barnstead 
International, Dubuque, Iowa, USA). Sodium chloride was purchased from Acros Organics 
(Belgium). 
Study Population 
Six female volunteers, aged 19-55 years, participated in the study. All were healthy, had no 
history of skin disease, and did not suffer from any dermatological conditions at the time of 
the study. An information pack containing Volunteer Information Sheets, Notes for 
Volunteers, consent form and a cream application chart was given to each participant. The 
documents contained the project details and additional information about the cream. Any 
questions raised were answered appropriately and written informed consent was obtained 
from each participant. Participants were asked to refrain from applying any topical 
formulations to the test areas, i.e., their forearms, throughout the duration of the study and 
to avoid taking part in any activities that may affect the properties of the skin such as 
sunbathing, swimming, exfoliation and beauty treatments. They were also instructed to 
allow at least 2-3 hours post-application before engaging in activities that may change the 
environment of the treatment site; e.g., taking a bath/shower or sporting activities. The 




Treatment with a Zinc-containing Formulation 
®
Volunteers were asked to apply Sudocrem , a commercially available zinc-containing 
formulation, onto their ventral forearms for a period two weeks. The ventral forearm was 
divided into two regions, treated and untreated, by an imaginary line drawn from wrist to 
elbow. One arm was designated for cream application once a day, the other arm for three 
times a day. On the treated sides of each arm, 2ml of the zinc formulation was measured 
and applied using a (needleless) syringe either once or three times a day for two weeks. 
The cream was massaged onto the skin until a uniform layer was achieved. After ten 
minutes the excess cream was removed by gently wiping with a soft facial tissue (Fig. 1). 
Care was taken to avoid spreading the cream onto the untreated side. 
Fig. 1 The ventral forearm divided into treated and untreated sides. Sudocrem
® 
was applied, and after 10 
minutes, was carefully removed without contaminating the contralateral (control) side of the forearm 
When the cream was applied three times a day, treatments were conducted in the morning, 
afternoon and night. After applying the cream for two weeks the volunteers were subjected 
to a series of zinc extraction experiments. Cream application was discontinued 24 hours 
prior to these procedures. 
Zinc Extraction Methods 
1. Tape Stripping 
Prior to commencement of tape stripping, volunteers acclimatised to the laboratory 
environment for 20 minutes and the entire forearm was cleaned with an isopropyl alcohol 
wipe and allowed to dry before starting the procedure. A template with an aperture of 
approximately 2 cm diameter was firmly secured over the sampling site to delimit the area. 
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Systems Ltd. London, UK). A pre-weighed tape-strip (Sartorius AG SE-2F semi-
microbalance, Sartorius AG, Germany) was placed onto the sampling site and pressed 
firmly to ensure good contact between the two surfaces. The tape was then removed with 
one swift movement and TEWL re-measured. Alternate tape stripping and TEWL 
measurements were made until a value of approximately four times the baseline was 
achieved. The tapes were then re-weighed and the zinc subsequently extracted from them. 
The following day, the tapes were re-weighed, rolled and placed into 4 ml sample vials 
with 1.5 ml 10% acetic acid solution to extract the zinc. The vials were shaken overnight 
®
using an IKA HS 260 Basic shaker (IKA Werke GmbH & Co., KG, Germany) then stored 
before analysis. 
2. Reverse Iontophoresis 
Skin sites adjacent to those used for tape stripping were used for reverse iontophoresis, 
cleaned with isopropyl alcohol wipes and allowed to dry completely prior to starting the 
procedure. The reverse iontophoretic system consisted of two glass cylinders (volume = 5 
2
ml, surface area approximately 2 cm ) in which the anode and cathode were positioned. 
The chambers were firmly attached to the ventral forearm using medical adhesive tape and 
silicon grease (Fig. 2). The vials were fitted with caps through which the silver-silver 
chloride (Ag/AgCl) electrodes were introduced. The two chambers were positioned about 6 
cm apart. 





Each chamber was filled with 3 ml of 3 mM saline solution. Current (0.3 mA/cm ), was 
supplied from a commercially-available, U.S. Food and Drug Administration-approved 
device, the Phoresor II Auto (Iomed Inc., UT, USA) which also has the CE mark. After 15 
minutes of iontophoresis, the current was interrupted and the contents of the electrode 
chambers removed and stored. The chambers were refilled with fresh solution, and reverse 
iontophoresis was continued for a further 15 minutes to generate a second set of extraction 
samples. This procedure was carried out on both arms at both treated and untreated sides. 
3. Passive Extraction 
Passive extraction followed an identical procedure as that just described but did not, of 
course, involve the use of electrodes nor the application of current. 
Sample Analysis 
All samples were appropriately diluted with deionised water to ensure that the zinc 
concentration fell within the range of the analytical instrument. The samples were analysed 
at the University of Bristol, Department of Earth Sciences using a JY Horiba Ultima 
inductively coupled plasma sequential atomic emission spectrometer (ICP-AES) (JY 
Horiba, Japan) fitted with a Burgener T2100 Nebulizer and JY Horiba AS421 autosampler 
set at a wavelength of 213.856 nm. Calibration standards were prepared from dilution of 
1000 ppm Zinc Standard for ICP from Primar F (Fisher Scientific UK Ltd., Loughborough, 
UK). 
Data Analysis 
SC thicknesses were calculated from the TEWL measurements recorded during tape 
stripping using the approach described in Chapter 2. 
Statistical Analysis 
Normality tests, non-linear regression and statistical analyses were performed using 
®
GraphPad Prism 4.00 software (Graph Pad Software Inc., San Diego, CA, USA). 
Statistical significance between data sets was determined via paired two-tailed t-test and 
one-way ANOVA where appropriate. The confidence interval was adjusted to 95% and the 
significance level set at P < 0.05. Outliers, determined by Grubb’s test 
(http://www.graphpad.com/quickcalcs/index.cfm), were removed from data analysis. 
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Results 
®
Sudocrem application frequency comparison 
The effect of application frequency on the amount of zinc delivered to the skin was 
investigated. 
1. Tape stripping 
Stratum corneum thicknesses on the forearm of the six volunteers’ ranged from 4.6 - 17.1 
µm with an average (±SD) thickness of 11.0 ± 3.6 µm. 
The amounts of zinc extracted from the tape strips as a function of depth (x) within the 
stratum corneum are shown in Fig. 3. Controls (untreated skin) contain the least amounts 
of zinc (i.e., endogenous levels) with the upper layers of the stratum corneum containing 
more than those deeper into the membrane. 
Fig. 3 Profiles of zinc as a function of position within the stratum corneum. Black, blue and red symbols 
represent control, once and three times a day Sudocrem
® 
application, respectively. 
Normalisation of stratum corneum thickness allows inter- and intra-variation in zinc 
content of each volunteer to be examined and compared (Fig. 4) and quite clearly separates 
the control data from those of the treated skin. However, since the amount of zinc in each 
sample is dependent on the mass of stratum corneum removed, (and this varies from tape 
to tape), the data need to be further normalised before the most appropriate comparisons 
can be made. 
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Fig. 4 Amounts of zinc per sample as a function of normalised stratum corneum thickness 
Calculating the amounts of zinc per unit mass of stratum corneum standardises the amount 
of zinc detected at different depths of the stratum corneum. Though this manipulation 
further separates the control group from the treatment groups, no segregation between once 
and three times a day treatments is obvious (Fig. 5) 
Fig. 5 Further normalisation of the amounts of zinc (quantity per unit mass of stratum corneum) as a function 
of normalised stratum corneum depth 
The cumulative amounts of zinc in the stratum corneum were also determined and are 
plotted as a function of stratum corneum position in Fig. 6. Though the control group is 
well separated from the treatment groups, overlap of the data from the latter is still evident. 
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Fig. 6 Cumulative zinc extracted from tape strips as a function of position in the stratum corneum 
A statistical analysis of cumulative zinc uptake into the stratum corneum following once, 
®
or three times a day treated with Sudocrem was undertaken and a two-tailed paired t-test 
revealed a significant difference (P = 0.03) between both treatments despite the evident 
variability in the results (Fig. 7). 
Fig. 7 Cumulative amounts of zinc (mean ± SD, n = 12 for the control and n = 6 for x1 and x3 treatments) in 
stratum corneum treated with Sudocrem
® 
once and three times a day. The control reflects the endogenous 
zinc level in untreated skin. 
2. Reverse Iontophoresis

Zinc was extracted at both the anode and cathode chambers by reverse iontophoresis. 
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times a day than that which received just one. In both cases, the zinc extraction exceeded 
that from the control, untreated sites (Fig. 8). 
Cathode 
Mean cumulative amounts of zinc extracted was 0.69 ± 0.37 μg, 2.79 ± 1.34 μg and 2.93 ± 
1.74 μg from the control, once and three times daily treated sites, respectively. No 
significant difference, determined by two-tailed paired t-test, was detected between once 
and three times daily treated skin, where P = 0.79. 
Anode 
Mean cumulative amounts of zinc extracted from the anode chambers of the control, once 
and three times a day treated skin sites were 0.27 ± 0.21 μg, 0.86 ± 0.72 μg and 1.12 ± 0.86 
μg, respectively. Again, no significant difference was detected by a two tailed-paired t-test 
®
on data zinc collected from skin sites treated with Sudocrem , P = 0.20. Analysis using 
one-way ANOVA and Tukey’s Multiple Comparison test detected a significant difference 
in levels of zinc between the control and three times a day treated skin only (P < 0.05). 
Fig. 8 Reverse iontophoresis extraction of zinc (mean ± SD, n = 12, 6, 6 for control, cathodal and anodal 




3. Passive Extraction 
Extraction of zinc from the control areas and forearms of volunteers treated with 
®












0.48   0.33
 1.23   0.88
2.04   1.38
Sudocrem

























Absorption of Zinc from Sudocrem into Human Stratum Corneum In Vivo 
amounts of 0.48 ± 0.33 μg, 1.23 ± 0.88 μg and 2.04 ± 1.38 μg of zinc, respectively (Fig. 9). 
Statistical analyses performed using a two tailed-paired t-test showed a significant 
difference in levels of zinc detected between once and three times a day treatment (P = 
0.04). 
Fig. 9 Mean cumulative zinc (with standard deviations) detected in control, once and three times daily treated 
skin collected by passive extraction. 
Comparison of Extraction Techniques 
By comparing the extraction of zinc from the various skin sites after the different 
treatments, the efficiency of the methods used can be evaluated. 
1. Control 
Amounts of zinc extracted by tape stripping, RI cathodal, RI anodal and passive extraction 
were 7.15 ± 5.65 μg, 0.69 ± 0.37 μg, 0.27 ± 0.21 μg and 0.48 ± 0.33 µg, respectively. One-
way ANOVA shows a statistical significance between tape stripping and all other methods 
of zinc extraction (P < 0.0001) (Fig. 10). By separately performing two-tailed paired-t­
tests, significant differences between the remaining techniques were established between 
cathodal and anodal, and anodal and passive extractions with P = 0.0004 and P = 0.006, 
respectively. No significant difference was found between cathodal and passive extraction 
(P = 0.11). 
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2. Once a day Sudocrem application 
Amounts of zinc extracted by tape stripping, RI cathodal, RI anodal and passive extraction 
were 42.7 ± 36.5 μg, 2.79 ± 1.34 μg, 0.86 ± 0.72 μg and 1.23 ± 0.88 µg, respectively. A 
significant difference was detected between tape stripping and other extraction techniques 
by a one-way ANOVA and Tukey’s Multiple comparison test (P = 0.001). Two-tailed 
paired t-tests revealed significant differences between cathodal and anodal, and cathodal 
and passive extractions, with P = 0.01 and P = 0.03, respectively. No significant difference 
was found between anodal and passive extractions (P = 0.08). Mean cumulative zinc 
extraction was highest by tape stripping and least by reverse iontophoretic anodal 
extraction (Fig. 10). 
®
3. Three times a day Sudocrem application 
Amounts of zinc extracted by tape stripping, RI cathodal, RI anodal and passive extraction 
were 59.6 ± 45.9, 2.93 ± 1.74, 1.12 ± 0.86 and 2.04 ± 1.38 µg, respectively. Tape stripping 
was again the most efficient and effective method to extract zinc from the skin (Fig. 10). 
One-way ANOVA indicated a significant difference between the levels of zinc extracted 
by tape stripping compared to the other methods used (P = 0.0004). Significant differences 
were also detected between cathodal and anodal, cathodal and passive, and anodal and 
passive extractions by two-tailed paired t-tests with P = 0.01, P < 0.01, and P < 0.05, 
respectively. 
Fig. 10 Mean cumulative amounts of zinc extracted by tape stripping, reverse iontophoresis (cathode and 
®
anode) and passive extraction, from a) the control (untreated skin) and skin treated with Sudocrem b) once 
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The amounts of zinc extracted from the skin using the different extraction techniques are 
collected in Table 1. The highest amounts of zinc were extracted from the skin by tape 
stripping, the least by reverse iontophoresis at the anode. For the control, once and three 
®
times daily applications of Sudocrem , the amounts of zinc recovered by tape stripping 
ranged from 11-27, 15-50, and 20-53 times greater than the other methods used, 
respectively. 
Table 1 Summary of cumulative zinc (in micrograms; mean ± SD) extracted by tape stripping, 
reverse iontophoresis and passive extraction. P-values shown were derived by two-tailed 




Extraction Control x1 Sudocrem® x3 Sudocrem® Significantly 
paired t-test) 
method (untreated) application/day applications/day different? 
(between x1 and x3) 
TS 7.15 ± 5.65 42.7 ± 36.5 59.6 ± 45.9 0.03 Yes 
RI cathode 0.69 ± 0.37 2.79 ± 1.34 2.93 ± 1.74 0.79 No 
RI anode 0.27 ± 0.21 0.86 ± 0.72 1.12 ± 0.86 0.20 No 
RI total 0.95 ± 0.52 3.66 ± 1.82 4.05 ± 2.48 0.50 No 
PE 0.48 ± 0.33 1.23 ± 0.88 2.04 ± 1.38 0.04 Yes 
Discussion 
Prior to this study, the penetration of zinc oxide into human stratum corneum following 
®
application of Sudocrem had not been determined. 
The results clearly show that tape stripping recovers at least ten-fold more zinc from 
stratum corneum than either passive or reverse iontophoretic extraction (Fig. 10). Tape 
stripping recovers both the solubilised zinc in the stratum corneum and also the solid, 
undissolved form that was sequestered in crevices and furrows of the skin. This material 
may not necessarily reflect the amount of bioavailable drug since not all the zinc 
‘recovered’ had penetrated into the stratum corneum. This is supported by evidence from 
previous work where formulations were trapped in skin furrows (19) and appendages. In 
that study, the dermatopharmacokinetics of betamethasone 17-valerate (BMV) were 
investigated. Higher levels of the drug were observed when the skin was cleaned with dry 
paper towel as opposed to an isopropyl alcohol wipe.(19) The experiment revealed that 
whilst the apparent delivery of BMV appeared to have decreased after using the latter, the 
diffusivity remained effectively unchanged between the cleaning methods indicating that 




sequestered formulation in the furrows.(19) Further, as evident in scanning electron 
microscopic images of skin treated with various zinc preparations in Chapter 6, 
formulations were observed on hairs, hair shafts and on the skin surface. Accurate 
determination of bioavailability is dependent on cleaning procedures. With regards to 
passive and reverse iontophoretic extractions, these procedures can only recover the zinc 
dissolved in the skin present in the free ion form. Since zinc oxide is very insoluble ­
approximately 0.16 mg/100 ml,(20, 21) it follows that the amounts of zinc recovered in the 
solutions are low. Further, zinc in the solid state will not be extractable either passively or 
by reverse iontophoresis. As expected, zinc is more efficiently extracted by reverse 
iontophoresis to the cathode. However, this is dependent on its presence as zinc ions in 
solution. The differential between the tape stripping results and those by reverse 
iontophoresis, therefore, between mobile zinc (i.e., that which has become available to the 
stratum corneum in molecular form) and total zinc trapped in the stratum corneum which 
includes, mainly, the element on the form of solid zinc oxide. 
In summary, tape stripping recovered more zinc from the stratum corneum than passive or 
reverse iontophoretic extraction. However, not all zinc recovered by tape stripping was that 
which had penetrated in the stratum corneum. Zinc that was trapped in furrows in the solid 
state form was also recovered. Reverse iontophoresis at the cathode recovered more zinc 
than at the anode due to the attraction between positive zinc ions and the negative cathode. 





Absorption of Zinc from Sudocrem into Human Stratum Corneum In Vivo 
References 
1. 	 BNF for Children 2006: BMJ Publishing Group Ltd, London, UK; 2006. 
2.	 Cross SE, Innes B, Roberts MS, Tsuzuki T, Robertson TA, McCormick P. Human 
skin penetration of sunscreen nanoparticles: In-vitro assessment of a novel 
micronized zinc oxide formulation. Skin Pharmacology and Physiology. 
2007;20(3):148-54. 
3.	 Nohynek GJ, Lademann J, Ribaud C, Roberts MS. Grey goo on the skin? 
Nanotechnology, cosmetic and sunscreen safety. Critical Reviews in Toxicology. 
2007;37(3):251-77. 
4.	 Newman MD, Stotland M, Ellis JI. The safety of nanosized particles in titanium 
dioxide- and zinc oxide-based sunscreens. Journal of the American Academy of 
Dermatology. 2009;61(4):685-92. 
5.	 Gamer AO, Leibold E, van Ravenzwaay B. The in vitro absorption of microfine zinc 
oxide and titanium dioxide through porcine skin. Toxicology in Vitro. 
2006;20(3):301-7. 
6.	 Zvyagin AV, Zhao X, Gierden A, Sanchez W, Ross JA, Roberts MS. Imaging of zinc 
oxide nanoparticle penetration in human skin in vitro and in vivo. Journal of 
Biomedical Optics. 2008;13(6):Article No.: 064031. 
7.	 Roberts MS, Roberts MJ, Robertson TA, Sanchez W, Thorling C, Zou YH, et al. In 
vitro and in vivo imaging of xenobiotic transport in human skin and in the rat liver. 
Journal of Biophotonics. 2008;1(6):478-93. 
8.	 EUROPA. European Union's Scientific Committee on Cosmetic Products and Non-
Food Products. Opinion of the scientific committee on cosmetic products and non­
food products intended for consumers concerning zinc oxide. Brussels (Belgium): 
European Commission; 2003 [July 2010]; Available from: 
http://ec.europa.eu/health/ph_risk/committees/04_sccp/04_sccp_en.htm. 
9.	 Eberlein-Konig B, Schafer T, Huss-Marp J, Darsow U, Mohrenschlager M, Herbert 
O, et al. Skin surface pH, stratum corneum hydration, trans-epidermal water loss and 
skin roughness related to atopic eczema and skin dryness in a population of primary 
school children. Acta Dermato-Venereologica. 2000;80(3):188-91. 
10.	 Yosipovitch G, Papoiu ADP. What causes itch in atopic dermatitis? Current Allergy 
and Asthma Reports. 2008;8(4):306-11. 




12.	 Wuthrich B, Cozzio A, Roll A, Senti G, Kundig T, Schmid-Grendelmeier P. Atopic 
eczema: Genetics or environment? Annals of Agricultural and Environmental 
Medicine. 2007;14(2):195-201. 
13.	 Holm EA, Wulf HC, Thomassen L, Jemec GBE. Instrumental assessment of atopic 
eczema: Validation of transepidermal water loss, stratum corneum hydration, 
erythema, scaling, and edema. Journal of the American Academy of Dermatology. 
2006;55(5):772-80. 
14.	 Plotz SG, Ring J. What's new in atopic eczema? Expert Opin Emerg Drugs. 
2010;15(2):249-67. 
15.	 Rudikoff D, Lebwohl M. Atopic dermatitis. Lancet. 1998;351(9117):1715-21. 
16.	 Bender BG, Ballard R, Canono B, Murphy JR, Leung DYM. Disease severity, 
scratching, and sleep quality in patients with atopic dermatitis. Journal of the 
American Academy of Dermatology. [Article]. 2008 Mar;58(3):415-20. 
17.	 Krakowski AC, Eichenfield LF, Dohil MA. Management of atopic dermatitis in the 
pediatric population. Pediatrics. 2008;122(4):812-24. 
18.	 Cork MJ, Danby S, Vasilopoulos Y, Moustafa M, MacGowan A, Varghese J, et al. 
Gene-environment interactions in atopic dermatitis. Drug Discovery Today: Disease 
Mechanisms. 2008(of Publication: Spring 2008):5(1)(pp e11-e31), 2008. 
19.	 Wiedersberg S, Leopold CS, Guy RH. Dermatopharmacokinetics of betamethasone 
17-valerate: Influence of formulation viscosity and skin surface cleaning procedure. 
European Journal of Pharmaceutics and Biopharmaceutics. [Article]. 2009 
Feb;71(2):362-6. 
20.	 Wikipedia.org. Zinc Oxide. Wikipedia; 2010 [updated 19/07/10; cited 2010 
21/07/10]; Zinc Oxide information]. Available from: 
http://en.wikipedia.org/wiki/Zinc_oxide. 
21.	 OSHA - Occupational Safety & Health Guideline for Zinc Oxide. Washington, DC: 



















The main objective of this thesis was to investigate the in vitro delivery of zinc from a 
novel zinc lactate formulation and to compare performance with that of already 
commercially available zinc oxide preparations. In the process leading up to the 
percutaneous penetration experiments for zinc, two methodologies were established to 
firstly enable the assessment and characterisation of skin barrier function, and secondly, 
analysis of zinc in the stratum corneum to be quantified by extraction of the tape strips. 
The former was achieved using minimally invasive procedures; tape stripping and 
transepidermal water loss measurements, and the latter, by tape stripping and analysis of 
samples by atomic absorption spectroscopy or inductively coupled plasma-atomic emission 
spectroscopy. The methodologies developed were effective, simple, non-invasive and 
inexpensive. Further, the findings of Chapter 2 - the short term application of Aqueous 
Cream BP caused skin atrophy and increased percutaneous penetration, was published in 
the British Journal of Dermatology and is already impacting the way Aqueous Cream BP is 
used for atopic eczema as an emollient.(1) 
The results obtained in Chapter 4 confirmed what numerous previous studies had reported; 
that the percutaneous penetration of zinc into the skin was, at best, minimal and was 
mainly detected in the outer layers of the stratum corneum. The investigation of 
commercial preparations in this thesis provide further evidence that formulation of a novel 
treatment for eczema that is able to deliver zinc to the skin more efficiently is needed. 
Development of the novel 1% w/w zinc lactate formulation in Chapter 5 afforded increased 
penetration of zinc into the skin. The results show that zinc uptake, when represented as 
percentage of the applied dose, from 1% w/w zinc lactate cream, was higher than all 
formulations tested (i.e., aqueous zinc chloride solutions, zinc and castor oil, Sudocrem®, 
Morhulin® and 2% w/v zinc lactate). The rationale behind this could be due to (i) the use of 
penetration enhancers or detergents that would aid the absorption of zinc into the skin, (ii) 
the use of small particle size, since these particles would penetrate more easily into the 
skin, and (iii) the incorporation of oil into the formulation would occlude the surface of the 
skin which would also enhance percutaneous absorption.(2) 
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Conclusions & Further Work 
In Chapter 6, the distribution of zinc on the surface of the skin and the effects of different 
cleaning procedures, (wiping with a dry paper towel versus rinsing under deionised water), 
on zinc disposition were studied. Scanning electron microscopy (SEM) was used to image 
the skin before and after treatment the with various zinc preparations. Passive diffusion 
with 5% and 50% w/v ZnCl2 showed that the higher concentration solution left visible 
deposits on the surface of the skin and on hairs. These deposits were not present after the 
rinsing the skin under water indicating that the substance may have well been ZnCl2 since 
it is highly water soluble. Further, these deposits were not observed on the control 
(untreated) skin. The images also showed that the application of Morhulin® ointment left a 
thin coating on the surface of the skin which, even after being cleaned with an isopropyl 
alcohol swab, was visible across the entire skin surface. Energy dispersive x-ray (EDX) 
spectroscopy and element mapping was used to qualitatively examine the amounts and 
distribution of zinc on the skin. Both EDX spectra and element maps showed that the 
concentration of zinc applied to the skin correlated to the amounts present on the surface. 
Both techniques were also used to compare amounts of zinc on the skin surface after 
cleaning with dry paper towels and rinsing under deionised water. Spectra and element 
maps showed that washing with deionised water removed relatively large quantities of zinc 
from the skin. Finally, element mapping showed that zinc did not have any affinity for a 
particular site on the skin and that it was distributed evenly across the surface. 
The final experimental chapter involved the in vivo testing of Sudocrem® (15.25% w/v 
ZnO) on human forearms and the elucidation of the most effective method for zinc 
extraction from the skin using tape stripping, reverse iontophoresis and passive extraction. 
Tape stripping proved to be the most efficient method for the extraction of zinc from the 
skin. The higher levels of zinc measured using this method was most likely a result of 
extracting zinc from formulation that was sequestered in skin furrows and other 
appendages together with zinc that was solubilised in the skin. With regard to reverse 
iontophoresis and passive extraction, the poor extraction efficiency could be explained by 
the fact that only zinc in the free ion form could be extracted from the skin and none from 
the semi-solid preparation remaining on the skin in crevices and appendages. 
In conclusion, methods for assessing and characterising skin barrier function, extraction 
and quantification of zinc in skin have been successfully developed. The in vivo 
application of Sudocrem® to human stratum corneum has shown that limited quantities of 




highest amounts of zinc from the skin followed by cathodal reverse iontophoresis. 
Scanning electron microscopy, EDX spectroscopy and element mapping allowed the 
distribution and relative quantities of zinc in the skin to be examined. The effects of 
cleaning procedures on the concentration of zinc on the skin and effects on skin structure 
were also deduced.  
Finally, preliminary research has shown that zinc can be delivered (albeit quite poorly) to 
the skin and that the percentage of the applied dose of zinc delivered from commercial 
preparations in vitro, zinc chloride and 2% w/v zinc lactate ranges from 0.004 - 0.04%. 
The formulation of a 1% w/w zinc lactate cream increased delivery to the skin by 
approximately double that of previously tested formulations (0.07% of the applied dose). 
The novel topical formulation for the treatment of the skin barrier in atopic eczema is 
therefore a promising starting point since not only can more zinc be delivered from the 
formulation to inhibit protease activity, suppress colonisation of S.aureus and aid wound 
healing but it also benefits the skin by restoring the natural pH which increases the 
production of sphingosine, providing hydration to the stratum corneum and decreasing 
scaling.(3-8) It is clear that the formulation offers many beneficial properties that can treat 
symptoms of eczema and aid barrier repair, however, further investigation and 




Conclusions & Further Work 
Further Work 
Detrimental effects of zinc deficiency on the skin barrier have been well documented and 
research has shown that zinc can aid in wound healing. In the development of a novel 
topical formulation, it is important that the therapeutic dose is known. Therefore, it is 
proposed that further investigations are needed in this respect. This could be achieved by 
the application of various concentrations of zinc on controlled wounds and recording the 
rate of healing. Optimum zinc concentration for the formulation could be deduced in this 
manner. 
Since the experiments carried out in this thesis have been conducted on the intact skin 
barrier (in vitro and in vivo), the percutaneous penetration of zinc through damaged skin 
should be investigated. The simplest and least expensive means by which this could be 
achieved is to perturb the stratum corneum via tape stripping.(9) This would, in effect, 
allow the stratum corneum to be partially bypassed and therefore, the compromised skin 
barrier that occurs in eczema to be mimicked and a more accurate representation of zinc 
uptake to be deduced. 
As mentioned previously, sodium lauryl sulphate (SLS) is a chemical known to alter the 
skin barrier and has been used in many investigations to study the penetration of 
substances through damaged skin.(10-12) For in vivo studies, as discussed in Chapter 2, the 
application of SLS at approximately 1% concentration should suffice to induce changes in 
the skin barrier and increase permeability to mimic the damaged stratum corneum in 
eczema. 
Further, the use of iontophoresis to deliver zinc to the skin could be explored. (9, 13, 14) 
This method may be utilised directly on eczematous lesions to deliver zinc to the skin to 
aid healing of the wound and restoration of the skin barrier. This method would require the 
zinc to be in free ion form and a suitable vehicle would be necessary. It is a relatively pain 
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